
TORONTO, Dec. 14 /CNW/ - Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, today announced its results for the fourth quarter ended October 31, 2007. (All amounts are in U.S. dollars unless otherwise indicated.)
The consolidated results for the fourth quarter of 2007 and comparative prior periods presented in this news release reflect the results for the Company's continuing operations. The results for Niagara-Burlington operations have been segregated and presented separately as discontinued operations in the consolidated financial statements.
Financial Results
Fourth Quarter Ended October 31, 2007
Compared With Fourth Quarter Ended October 31, 2006
- Revenues from continuing operations were $166.8 million, an increase
of 1%;
- EBITDA before repositioning expenses from continuing operations was
$21.2 million (12.7% of revenues), compared with $18.8 million (11.3%
of revenues);
- EBITDA before repositioning expenses from continuing operations
included foreign exchange gains of $5.8 million;
- Revenues and EBITDA before repositioning expenses from continuing
operations, excluding Puerto Rico, were $151.9 million and
$30.4 million, respectively, compared with $131.9 million and
$18.5 million;
- Revenues and EBITDA before repositioning expenses from discontinued
operations were $6.8 million and $0.5 million, respectively, compared
with $9.4 million and $0.8 million a year ago;
- The loss from continuing operations for the quarter was $9.1 million
(9.9 cents per share), compared with a loss of $22.2 million
(23.8 cents per share) a year ago;
- The net loss including discontinued operations for the quarter was
$7.5 million (8.2 cents per share) compared with a net loss of
$22.4 million (24.1 cents per share) a year ago.
Twelve Months Ended October 31, 2007
Compared With Twelve Months Ended October 31, 2006
- Revenues from continuing operations were $677.1 million versus
$674.7 million;
- EBITDA before repositioning expenses from continuing operations
improved by 27% to $90.3 million (13.3% of revenues), up from
$70.9 million (10.5%);
- EBITDA before repositioning expenses from continuing operations
included foreign exchange gains of $8.9 million;
- Revenues and EBITDA before repositioning expenses from continuing
operations, excluding Puerto Rico, were $577.3 million and
$108.6 million, respectively, compared with $544.9 million and
$69.5 million;
- Revenues and EBITDA before repositioning expenses from discontinued
operations were $35.2 million and $2.8 million, respectively, compared
with $37.5 million and $2.9 million;
- The loss from continuing operations was $84.5 million (91.0 cents per
share) compared with a loss of $288.7 million ($3.11 per share) a year
ago;
- The net loss including discontinued operations for the year was
$94.6 million ($1.02 per share) compared with a net loss of
$288.2 million ($3.10 per share) a year ago.
"Fiscal 2007 was a year of considerable improvement in the financial performance of most of our operations," said Riccardo Trecroce of Patheon Inc. "Our European, Canadian and Cincinnati sites continued to grow, generating revenues of $577.3 million, up 6% over 2006. Growth was particularly strong in Europe, where Rx manufacturing revenues grew by 23% year-over-year due to high demand for our specialized manufacturing capabilities. Our global PDS revenues grew 19% to $116.5 million, and we successfully launched three more new products on behalf of our clients during the year.
"This strong performance has been overshadowed by the results of our Puerto Rico operations, which continued to deteriorate in the fourth quarter," Mr. Trecroce said. "Increased losses were driven in part by significantly lower revenues in the fourth quarter for Omnicef(R), manufactured at the Carolina site, due to generic competition. There also were increased losses at the Caguas facility, due to lower volumes of several significant products and various operating inefficiencies."
Puerto Rico restructuring
As previously announced, Patheon has been conducting a comprehensive review of the Puerto Rico operations, with a focus on restructuring the operations, eliminating operating losses and developing a long-term plan for the business.
As a result of this review, Patheon has decided to retain and continue to streamline its facilities in Caguas and Manati, and divest its facility in Carolina, Puerto Rico.
The Carolina site is a 230,000-square-foot facility, with approximately 200 employees, that specializes in the manufacture of oral cephalosporin solid dosage forms, including tablets, capsules and powders for suspension. It currently manufactures four products on behalf of six clients.
"We have concluded that Carolina - a high-quality site with specialized capabilities and expertise - would be of greater strategic value to another company with a focus on manufacturing oral cephalosporins," said Mr. Trecroce. "This divestiture will allow us to focus on improving operating performance and growing our business at the Caguas and Manati facilities."
It is anticipated that the purchaser will assume responsibility for the staff at the facility, and contracts with third parties subject to their approval. Patheon has retained an advisor to manage the sale of the Carolina site.
Patheon plans to retain its facilities at Caguas and Manati, with the objective of returning the Puerto Rico operations to breakeven at the EBITDA level by the end of fiscal 2008. With new management in place in Puerto Rico, Patheon plans to continue an extensive program to improve operating performance, improve quality and training systems, reduce overhead costs and pursue new business opportunities for these sites. During the fourth quarter, the size of the workforce was reduced by an additional 40 positions at Caguas, resulting in a total workforce at Caguas and Manati of approximately 775 positions at fiscal year end. In the second half of fiscal 2007, the Company secured commitments to manufacture four additional products on behalf of three clients that it expects to begin contributing to results in the latter half of 2008.
Canadian site network restructuring
On December 6, 2007, Patheon announced that it had entered into a definitive agreement to sell its Niagara-Burlington over-the-counter pharmaceutical manufacturing business to Pharmetics Inc. Pharmetics will acquire the assets at Patheon's facilities in Fort Erie and Burlington (Gateway Drive), Ontario, provide employment to the active workforce and, subject to the assignment of third-party contracts, continue manufacturing the existing products at the sites. The transaction is expected to be completed on or about January 31, 2008, subject to closing conditions.
"The agreement with Pharmetics marked the successful conclusion to the Niagara-Burlington OTC divestiture process," said Mr. Trecroce. "By divesting of this business, Patheon can now focus capital and resources on the areas of its business with the greatest potential for higher-margin growth."
Fourth-quarter operating results from continuing operations
Fourth-quarter revenues increased by $1.0 million, or 1%, to $166.8 million over the same period a year ago. Pharmaceutical development services ("PDS") revenues grew by $4.1 million and over-the-counter ("OTC") revenues by $2.3 million, while prescription ("Rx") revenues declined by $5.4 million.
Revenues from Rx manufacturing services declined by $5.4 million or 4% over the same period a year ago, with strong year-over-year growth in Europe offset by declines in Puerto Rico and Canada. The revenue growth in Europe reflects the full commercial production of multiple products transferred into Patheon's sites in Italy and France by two clients. Rx revenues declined in Puerto Rico year-over-year, due to significantly lower revenues for Omnicef(R) in the fourth quarter following the emergence of generic competition in May 2007, lower volumes of other products, and the absence of orders for Zocor(R), which lost patent protection in 2006. Rx revenues were down in Canada, primarily due to API delivery delays for products manufactured on behalf of a major client at Toronto Region Operations.
Revenues from pharmaceutical development services increased by $4.1 million, or 14%, due to solid growth at the Swindon and Cincinnati PDS operations. Patheon is currently developing 199 new products on behalf of its clients, up from 171 a year ago.
Consolidated EBITDA before repositioning expenses was $21.2 million in the fourth quarter, up from $18.8 million a year ago. The EBITDA margin before repositioning expense was 12.7% in the fourth quarter, compared with 11.3% in the fourth quarter of 2006.
Operating expenses were reduced in the fourth quarter by foreign exchange gains of $5.8 million. These gains principally arose from the re-evaluation of the U.S. dollar denominated debt in Canada and benefits from the Company's cash flow hedging program. Operating expenses were further reduced in the fourth quarter as a result of an actuarial gain of $4.3 million arising from a decision to phase out certain post-retirement health benefits in Canada.
In Canada, despite a decline in revenues, particularly at Toronto Region Operations, EBITDA before repositioning expenses from commercial manufacturing operations was $6.9 million, or $1.7 million higher than the same period a year ago. This improvement reflects the inclusion of a significant portion of the actuarial gains resulting from the amendment to the Company's post- retirement health benefit plans. EBITDA before repositioning expenses was not significantly impacted by the strengthening of the Canadian dollar relative to the U.S. dollar in the fourth quarter, due to gains from the Company's foreign exchange cash flow hedging program.
EBITDA before repositioning expenses from U.S. operations was a loss of $4.5 million, compared with a profit of $5.7 million in the same period a year ago. The decline was attributable to significantly lower volumes of Omnicef at Carolina Operations and reduced volumes of high-margin products and operating inefficiencies at Caguas Operations. In Cincinnati, EBITDA before repositioning expenses continued to improve due to strong volume growth and increased operating efficiencies.
In Europe, EBITDA before repositioning expenses from the commercial manufacturing operations was $3.8 million, or $0.3 million lower than the same period a year ago. The benefits of higher revenues were offset by additional variable compensation costs, incremental costs relating to production delays at Swindon Operations and foreign exchange losses.
EBITDA before repositioning expenses from global pharmaceutical development services was $9.4 million, or $3.2 million higher than the same period a year ago. The increase reflects improved revenue growth at the Cincinnati and Swindon PDS operations.
Outlook
Due to normal shutdowns during December, revenues in the first quarter of 2008 are expected to be lower than the fourth quarter of 2007.
FORWARD-LOOKING STATEMENTS
Cautionary Note
This news release contains forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities.
PLEASE REFER TO THE CAUTIONARY NOTE AT THE END OF THE MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ("MD&A") ATTACHED TO AND FORMING PART OF THIS NEWS RELEASE.
WEBCAST CONFERENCE CALL WITH ANALYSTS
Patheon Inc. will host a webcast conference call with financial analysts on its fourth quarter results on Friday, December 14, 2007 at 10:00 a.m. (Eastern Standard Time). The call will begin with a brief presentation, followed by a question-and-answer period with investment analysts. Interested parties are invited to access the live call, via telephone, in listen-only mode, at (416) 915-5761 (Toronto and International) or toll free at (800) 732- 6179 (U.S., including Puerto Rico). Listeners are encouraged to dial in five to 15 minutes in advance to avoid delays. A live audio webcast, with a slide presentation, will also be available via the web at www.patheon.com. An archived version of the Q4 webcast will be available on www.patheon.com for three months.
ABOUT PATHEON
Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing 5,100 people and serving a client base of 250 pharmaceutical and biotechnology companies.
Consolidated Statements of Earnings (Loss)
(unaudited)
Three months ended Twelve months ended
October 31, October 31,
% %
2007 2006 change 2007 2006 change
-------------------------------------------------------------------------
(in thousands
of U.S. dollars,
except per share
amounts) $ $ $ $
-------------------------------------------------------------------------
Revenues 166,792 165,750 0.6% 677,074 674,659 0.4%
Operating
expenses 145,558 146,988 -1.0% 586,756 603,783 -2.8%
---------------------------- ----------------------------
Earnings
before the
following: 21,234 18,762 13.2% 90,318 70,876 27.4%
---------------------------- ----------------------------
(as a % of
revenues) 12.7% 11.3% 13.3% 10.5%
Asset
impairment
charge
(note 4) - - 48,580 254,661 -80.9%
Repositioning
expenses
(note 7) 6,714 12,998 -48.3% 15,800 12,998 21.6%
Depreciation
and
amortization 10,436 9,676 7.9% 40,979 38,766 5.7%
Amortization
of
intangible
assets 1,093 2,182 -49.9% 6,687 11,871 -43.7%
Foreign
exchange
loss (note 8) - - 858 -
Interest 7,468 6,247 19.5% 29,167 21,333 36.7%
Refinancing
expenses
(note 11) - - 13,471 1,643 719.9%
Amortization
of
deferred
financing
costs - 346 - 944
Write-off of
deferred
financing
costs
(note 11) - - - 6,332
---------------------------- ----------------------------
Loss before
income taxes (4,477) (12,687) 64.7% (65,224) (277,672) 76.5%
Provision for
income taxes 4,573 9,475 51.7% 19,234 11,047 74.1%
---------------------------- ----------------------------
Loss from
continuing
operations (9,050) (22,162) 59.2% (84,458) (288,719) 70.7%
---------------------------- ----------------------------
(as a % of
revenues) -5.4% -13.4% -12.5% -42.8%
Earnings (loss)
from
discontinued
operations
(note 5) 1,528 (254) 701.6% (10,143) 569 -1882.6%
---------------------------- ----------------------------
Net loss for
the period (7,522) (22,416) 66.4% (94,601) (288,150) 67.2%
---------------------------- ----------------------------
---------------------------- ----------------------------
Basic and
diluted
earnings
(loss)
per share
From
continuing
operations (9.9 (23.8 (91.0 (310.8
cents) cents) 58.4% cents) cents) 70.7%
From
discontinued
operations 1.7 (0.3 (10.9 0.6
cents cents) 666.7% cents) cents -1916.7%
---------------------------- ----------------------------
(8.2 (24.1 (101.9 (310.2
cents) cents) 66.0% cents) cents) 67.2%
---------------------------- ----------------------------
Average number
of shares
outstanding
during period
(in thousands): `
Basic and
diluted 92,473 92,919 -0.5% 92,834 92,868 0.0%
---------------------------- ----------------------------
see accompanying notes
Consolidated Balance Sheets
(unaudited)
As at As at
October 31, October 31,
2007 2006
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Assets
Current
Cash and cash equivalents 30,557 50,723
Accounts receivable 130,801 117,705
Inventories 88,729 72,057
Prepaid expenses and other 12,347 6,615
Assets held for sale (note 5) 9,843 8,341
-----------------------
Total current assets 272,277 255,441
-----------------------
Capital assets (note 4) 487,423 467,365
Intangible assets (note 4) 8,718 41,447
Deferred costs 8,878 9,717
Future tax assets 31,055 21,827
Goodwill 3,658 3,077
Investments 946 586
Assets held for sale (note 5) 16,662 26,723
-----------------------
829,617 826,183
-----------------------
-----------------------
Liabilities and Shareholders' equity
Current
Bank indebtedness 8,224 3,829
Accounts payable and accrued liabilities 163,721 140,254
Income taxes payable 4,684 879
Current portion of long-term debt (note 10) 11,902 283,717
Liabilities related to assets held for
sale (note 5) 3,174 2,527
-----------------------
Total current liabilities 191,705 431,206
-----------------------
Long-term debt (note 10) 203,647 62,071
Deferred revenues 25,994 23,366
Future tax liabilities 47,578 33,128
Convertible preferred shares
- debt component (note 10) 139,916 -
Other long-term liabilities 22,069 24,265
Long-term liabilities related to assets held
for sale (note 5) 1,523 1,416
-----------------------
Total liabilities 632,432 575,452
-----------------------
Shareholders' equity
Convertible preferred shares - equity
component (note 2 and 10) 15,925 -
Restricted voting shares (note 2) 391,967 400,721
Contributed surplus 4,049 3,829
Deficit (286,250) (189,900)
Accumulated other comprehensive income 71,494 36,081
-----------------------
Total shareholders' equity 197,185 250,731
-----------------------
829,617 826,183
-----------------------
-----------------------
see accompanying notes
Consolidated Statements of Changes in Shareholders' Equity
(unaudited)
Twelve months ended October 31,
2007 2006
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Convertible preferred shares - equity component
Balance at beginning of period - -
Shares issued during the period, net of issue
costs 15,925 -
-----------------------
Balance at end of period 15,925 -
-----------------------
Restricted voting shares
Balance at beginning of period 400,721 400,594
Shares issued during the period, net of
issue costs 24 127
Shares repurchased during the period, net
of transaction costs (8,778) -
-----------------------
Balance at end of period 391,967 400,721
-----------------------
Contributed surplus
Balance at beginning of period 3,829 2,901
Stock options 220 928
-----------------------
Balance at end of period 4,049 3,829
-----------------------
Retained earnings (deficit)
Balance at beginning of period (189,900) 98,250
Adjustment related to change in accounting
policy (note 1) (1,749) -
Net loss for the period (94,601) (288,150)
-----------------------
Balance at end of period (286,250) (189,900)
-----------------------
Accumulated other comprehensive income
Balance at beginning of period 36,081 38,106
Transition adjustment (note 1) (762) -
Other comprehensive income (loss) for the period 36,175 (2,025)
-----------------------
Balance at end of period 71,494 36,081
-----------------------
Total shareholders' equity at end of period 197,185 250,731
-----------------------
-----------------------
see accompanying notes
Consolidated Statements of Comprehensive Income (Loss)
(unaudited)
Three Twelve
months months
ended ended
October 31, October 31,
2007 2007
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Net loss for the period (7,522) (94,601)
------------------------
Other comprehensive income (loss), net of
income taxes (note 12)
Change in foreign currency gains on investments
in subsidiaries, net of hedging activities 18,145 30,787
Foreign currency losses on investments in
subsidiaries, net of hedging activities
reclassified to consolidated statement
of earnings (loss) - 2,793
Change in value of derivatives designated
as foreign currency and interest rate
cash flow hedges 2,522 3,723
Gains on foreign currency and interest rate
cash flow hedges reclassified to consolidated
statements of earnings (loss) (1,450) (1,128)
------------------------
Other comprehensive income for the period 19,217 36,175
------------------------
Comprehensive income (loss) for the period 11,695 (58,426)
see accompanying notes
Consolidated Statements of Cash Flows
(unaudited)
Three months Twelve months
ended October 31, ended October 31,
2007 2006 2007 2006
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $ $ $
-------------------------------------------------------------------------
Operating activities
Net loss from continuing
operations (9,050) (22,162) (84,458) (288,719)
Add (deduct) charges to
operations not requiring a
current cash payment
Asset impairment charge
(note 4) - - 48,580 254,661
Depreciation and amortization 11,529 11,858 47,666 50,637
Foreign exchange loss (note 8) - - 858 -
Foreign exchange gain on debt,
net of hedging (7,541) - (12,331) -
Accretive interest on
convertible preferred
shares (note 1) 3,573 - 7,054 -
Write-off of deferred
financing costs (note 11) - - - 6,332
Amortization of deferred
financing costs 151 346 1,657 944
Employee future benefits,
net of contributions (5,169) 319 (4,846) 1,112
Future income taxes 1,445 (3,514) 4,617 (6,678)
Amortization of deferred
revenues (505) (485) (2,021) (1,978)
Other 1,117 154 2,087 1,587
--------------------------------------
(4,450) (13,484) 8,863 17,898
Net change in non-cash working
capital balances related to
continuing operations 21,742 36,111 (2,442) 20,506
Increase in deferred revenues 8 - 2,065 9,614
--------------------------------------
Cash provided by operating
activities of continuing
operations 17,300 22,627 8,486 48,018
Cash provided by (used in)
operating activities
of discontinued operations
(note 5) (1,127) 715 3,105 4,212
--------------------------------------
Cash provided by operating
activities 16,173 23,342 11,591 52,230
--------------------------------------
Investing activities
Additions to capital assets
- sustaining (9,166) (7,088) (18,034) (16,975)
- project related (5,519) (17,791) (17,768) (49,617)
Net increase in investments (25) (49) (202) (49)
Increase in deferred
pre-operating costs (832) (625) (3,659) (2,204)
--------------------------------------
Cash used in investing
activities of continuing
operations (15,542) (25,553) (39,663) (68,845)
Cash used in investing
activities of discontinued
operations (note 5) - (476) (275) (907)
--------------------------------------
Cash used in investing activities (15,542) (26,029) (39,938) (69,752)
--------------------------------------
Financing activities
Increase (decrease) in bank
indebtedness (4,230) 3,041 3,532 (11,096)
Increase in long-term debt 15,456 42,443 198,108 416,389
Repayment of long-term debt (17,380) (11,790) (337,452) (364,800)
Issue of convertible preferred
shares (note 10) - - 150,000 -
Convertible preferred share
issue costs - equity component
(note 10) - - (1,213) -
Issue of restricted voting shares - 47 24 127
Repurchase of restricted voting
shares (note 2) (8,778) - (8,778) -
Decrease in restricted cash - - - 7,805
Increase in deferred
financing costs - (1,175) - (3,965)
--------------------------------------
Cash provided by (used in)
financing activities (14,932) 32,566 4,221 44,460
--------------------------------------
Effect of exchange rate changes
on cash and cash equivalents 4,362 847 3,960 1,278
--------------------------------------
Net increase (decrease) in
cash and cash equivalents
during the period (9,939) 30,726 (20,166) 28,216
Cash and cash equivalents,
beginning of period 40,496 19,997 50,723 22,507
--------------------------------------
Cash and cash equivalents,
end of period 30,557 50,723 30,557 50,723
--------------------------------------
--------------------------------------
see accompanying notes
Notes to Unaudited Consolidated Financial Statements for the
Year Ended October 31, 2007
(Dollar information in tabular form is expressed in
thousands of U.S. dollars)
1. Accounting policies
Basis of presentation
The accompanying unaudited consolidated financial statements have been
prepared by the Company in accordance with Canadian generally accepted
accounting principles ("GAAP") on a basis consistent with those followed
in the most recent audited consolidated financial statements except as
noted below. These consolidated financial statements do not include all
the information and footnotes required by generally accepted accounting
principles for annual financial statements and therefore should be read
in conjunction with the audited consolidated financial statements and
notes for the year ended October 31, 2006.
The preparation of the consolidated financial statements in conformity
with Canadian generally accepted accounting principles requires
management to make estimates and assumptions that affect: the reported
amounts of assets and liabilities; the disclosure of contingent assets
and liabilities at the date of the consolidated financial statements; and
the reported amounts of revenue and expenses in the reporting period.
Management believes that the estimates and assumptions used in preparing
its consolidated financial statements are reasonable and prudent,
however, actual results could differ from those estimates.
Changes in accounting policy
Effective November 1, 2006 the Company adopted the CICA Handbook Section
3855 "Financial Instruments - Recognition and Measurement", Section 3861
"Financial Instruments - Disclosure and Presentation", Section 3865
"Hedges" and Section 1530 "Comprehensive Income". The adoption of the new
standards resulted in changes in accounting for financial instruments and
hedges as well as the recognition of certain transition adjustments that
have been recorded in accumulated other comprehensive income. The
comparative interim consolidated financial statements have not been
restated except as noted below. The principal changes in the accounting
for financial instruments and hedges due to the adoption of these
accounting standards are described below:
Financial Assets and Financial Liabilities
------------------------------------------
An investment in shares of a publicly traded company have been designated
as held for trading and are accounted for at fair value, with changes in
the fair value being recorded in the consolidated statement of earnings
(loss). Prior to the adoption of the new standards, this investment was
accounted for on a cost basis, as adjusted for an other than temporary
decline in value. All other financial assets are accounted for on an
amortized cost basis and financial liabilities are accounted for on an
accruals basis, consistent with prior accounting policies.
Costs of obtaining bank and other debt financing that were previously
reported in deferred costs are now netted against the carrying value of
the related debt and amortized into interest expense using the effective
interest rate method. Prior to the adoption of the new standards, the
amortization of deferred financing costs was reported as a separate line
in the consolidated statement of earnings (loss) and the amortized
balance disclosed in deferred costs on the consolidated balance sheet.
In the second quarter of 2007 the Company also changed its accounting
policy relating to costs of obtaining bank and other debt financing.
Under the new policy all transaction costs, including fees paid to
advisors and other related costs, are expensed as incurred. Financing
costs, including underwriting and arrangement fees paid to lenders are
deferred and netted against the carrying value of the related debt and
amortized into interest expense using the effective interest rate method.
The Company previously deferred all transaction and financing costs
associated with obtaining bank and other debt financing. The Company
believes that the new policy is reliable and more relevant as it results
in a more transparent treatment of transaction costs that the Company has
incurred in its recent refinancing activities and in the carrying value
of debt.
The change in policy has been made retrospectively effective November 1,
2006 and had the effect of increasing the retained deficit at November 1,
2006 by $1,749,000 and reducing the interest expense and net loss for the
three months ended January 31, 2007 by $612,000. Refinancing expenses for
the twelve months ended October 31, 2007 include transaction costs
incurred in connection with the completion of the Company's senior
secured credit facilities and the debt component of the convertible
preferred shares of $11,889,000 (see note 11).
In 2006, the Company cancelled its interest rate swaps that were used as
a hedge against changes in interest payments on floating rate debt.
Deferred gains from the cancellation of these interest rate swaps that
had previously been recorded in accounts payable and accrued liabilities
were recorded in accumulated other comprehensive income. In the second
quarter of 2007, all remaining deferred gains on the interest rate swap
were reclassified to the consolidated statement of earnings (loss).
Derivatives and Hedge Accounting
--------------------------------
The Company enters into foreign exchange forward contracts to hedge its
exposure in foreign currency denominated cash flows and holds foreign
currency denominated debt as a hedge against the carrying value of its
equity investment in certain foreign currency denominated operations.
Prior to the adoption of the new standards, the Company accounted for
derivatives that met the requirements of hedge accounting on an accrual
basis. Under the new standards all derivatives, other than those
contracts that are entered into for the Company's own expected
requirements, are recorded at their fair value.
The effective portion of changes in the fair value of cash flow hedges
and hedges of net investments in foreign operations are recognized in
other comprehensive income. Amounts accumulated in other comprehensive
income are reclassified to the consolidated statement of earnings (loss)
in the period in which the hedged item affects the earnings (loss). Any
gain or loss in the fair value relating to the ineffective portion of a
hedge is recognized immediately in the consolidated statement of earnings
(loss).
Comprehensive Income (Loss) and Accumulated Other Comprehensive Income
----------------------------------------------------------------------
Comprehensive income (loss) is comprised of the Company's net loss and
other comprehensive income. Other comprehensive income includes foreign
currency translation gains and losses on net investments in self-
sustaining operations net of hedging activities and changes in the fair
value of derivative instruments designated as foreign currency and
interest rate cash flow hedges, all net of income taxes.
On transition to the new accounting standards, deferred after tax gains
from interest rate swaps of $656,000 and after tax losses on the fair
value of cash flow hedges of $1,418,000 were recorded in accumulated
other comprehensive income. Accumulated other comprehensive income also
includes gains on net investments in self sustaining foreign operations,
net of hedging activities previously recorded in cumulative translation
adjustment. As a result, the previously recorded cumulative translation
adjustment account has been eliminated and the balances have been
included in accumulated other comprehensive income. On transition to the
new standards, the comparative amounts of other comprehensive income for
the period only reflect the amounts previously recorded in the cumulative
translation adjustment account.
Convertible preferred shares
On April 27, 2007 the Company issued $150 million of convertible
preferred shares. The shares are considered to be a compound financial
instrument that contains both a debt component and an equity component.
On issuance of the convertible preferred shares, the fair value of the
debt component was determined by discounting the expected future cash
flows over the expected life using a market interest rate for a non-
convertible debt instrument with similar terms. The value is carried as
debt on an amortized cost basis until extinguished on conversion or
redemption. The remainder of the proceeds were allocated as a separate
component of shareholders' equity, net of transaction costs. Transaction
costs are apportioned between the debt and equity components based on
their respective carrying amounts when the instrument was issued.
On conversion, the carrying amount of the debt component and the equity
component are transferred to share capital and no gain or loss is
recognized.
The interest cost recognized in respect of the debt component represents
the accretion of the liability, over its expected life using the
effective interest method, to the amount that would be payable if
redeemed. The interest expense for the three and twelve months ended
October 31, 2007 includes a charge of $3,573,000 and $7,054,000,
respectively, for the accretive interest on the convertible preferred
shares.
2. Convertible preferred shares and restricted voting shares
The following table summarizes information on convertible preferred
shares, and restricted voting shares and related matters at October 31,
2007:
Outstanding Exercisable
Convertible preferred shares
Class I preferred shares series C and D 150,000
Restricted voting shares (previously common
shares) 90,624,388
Restricted voting share stock options 3,857,916 3,706,249
During the fourth quarter of 2007, the Company repurchased, through a
normal course issuer bid, 2,334,300 restricted voting shares at a cost of
$8,778,000.
The Company's articles were amended on April 26, 2007 to re-designate the
common shares as restricted voting shares. This occurred in connection
with the issuance of the convertible preferred shares. The holders of the
convertible preferred shares have the right to appoint three of nine
members of the Board of Directors. The holders of Patheon's restricted
voting shares have the right to elect the remaining members of the Board
of Directors. Under the rules of the Toronto Stock Exchange, voting
equity securities are not to be designated, or called, common shares
unless they have a right to vote in all circumstances that is not less,
on a per share basis, than the voting rights of each other class of
voting securities. Accordingly, the Company has amended its articles to
re-designate the common shares as restricted voting shares. This
re-designation involves only a change in the name of the securities; the
number of shares outstanding and the terms and conditions of the
outstanding shares are not affected by the change.
3. Segmented information
The Company is organized and managed as a single business segment, being
the provider of commercial manufacturing and pharmaceutical development
services.
Canadian and foreign continuing operations consist of:
Manufacturing location
Three months ended October 31, 2007
------------------------------------
Canada USA Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues by client's billing location:
Canada 3,529 166 233 3,928
USA 32,472 41,428 6,741 80,641
Europe 12,503 900 64,497 77,900
Other geographic areas 1,406 1,854 1,063 4,323
-------------------------------------------------------------------------
Total revenues 49,910 44,348 72,534 166,792
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Capital assets 120,808 119,483 247,132 487,423
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Goodwill 3,658 - - 3,658
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Manufacturing location
Three months ended October 31, 2006
------------------------------------
Canada USA Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues by client's billing location:
Canada 5,138 364 1,337 6,839
USA 35,731 57,719 3,768 97,218
Europe 9,661 339 49,565 59,565
Other geographic areas 499 - 1,629 2,128
-------------------------------------------------------------------------
Total revenues 51,029 58,422 56,299 165,750
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Capital assets 103,002 142,491 221,872 467,365
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Goodwill 3,077 - - 3,077
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Manufacturing location
Twelve months ended October 31, 2007
-------------------------------------
Canada USA Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues by client's billing location:
Canada 14,270 1,069 1,128 16,467
USA 137,389 196,690 17,757 351,836
Europe 39,235 3,127 254,547 296,909
Other geographic areas 4,197 2,146 5,519 11,862
-------------------------------------------------------------------------
Total revenues 195,091 203,032 278,951 677,074
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Manufacturing location
Twelve months ended October 31, 2006
-------------------------------------
Canada USA Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues by client's billing location:
Canada 21,323 856 1,930 24,109
USA 138,587 231,184 13,751 383,522
Europe 53,010 846 202,842 256,698
Other geographic areas 4,696 190 5,444 10,330
-------------------------------------------------------------------------
Total revenues 217,616 233,076 223,967 674,659
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Revenues are attributed to countries based on the location of the
client's billing address, capital assets are attributed to the country in
which they are located, and goodwill is attributed to the country in
which the entity to which the goodwill pertains is located.
Revenue information by service activity is as follows:
Three months ended October 31,
-----------------------------------
2007 2006
$ $
-------------------------------------------------------------------------
Commercial manufacturing -
prescription 119,226 71% 124,592 75%
Commercial manufacturing -
over-the-counter 14,855 9% 12,581 8%
Development services 32,711 20% 28,577 17%
-------------------------------------------------------------------------
166,792 100% 165,750 100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Twelve months ended October 31,
-------------------------------------------------------------------------
2007 2006
$ $
-------------------------------------------------------------------------
Commercial manufacturing -
prescription 514,069 76% 506,711 75%
Commercial manufacturing -
over-the-counter 46,549 7% 69,973 10%
Development services 116,456 17% 97,975 15%
-------------------------------------------------------------------------
677,074 100% 674,659 100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
4. Asset impairment charge
During the third quarter of 2007 it was determined that the carrying
value of the intangible assets and depreciable tangible capital assets
(collectively the "long-lived depreciable assets") at the Company's
operations in Carolina, Puerto Rico were impaired as a result of volume
declines arising from the genericization of Omnicef(R), this being the
largest single product that is manufactured at the facility. The Company
tested the recoverability of the long-lived depreciable assets at the
Carolina operations and determined that the expected future cash flows
over the economic life of the principal assets were less than the
carrying value of the long-lived depreciable assets. As a result the
Company recorded an impairment charge of $48,580,000; $26,043,000 for
intangible assets and $22,537,000 for tangible capital assets. The fair
value of the intangible assets was determined using a discounted cash
flow methodology and the fair value of the tangible capital assets was
based on a weighted average continued use and liquidation value.
During the third quarter of 2006 the Company determined that the carrying
value of the long-lived depreciable assets at the Company's operations in
Caguas and Manati, Puerto Rico and the goodwill associated with all of
the Puerto Rico operations were impaired as a result of certain events
which occurred during the third quarter of 2006. These events included:
continued deterioration in revenues culminating in a significant increase
in losses reported in the third quarter; suspension of production of a
major product due to concerns over product shelf life; the risk of a
decline in revenue of another major product as a result of the approval
by the U.S. Food and Drug Administration of a generic version of the
product; and the completion of a long range plan that showed a
significant reduction in earnings relative to prior forecasts.
The Company tested the recoverability of the long-lived depreciable
assets for all the Puerto Rico operations and determined that in Caguas
and Manati the expected future cash flows over the economic life of the
principal assets was less than the carrying value of the long-lived
depreciable assets. As a result the Company recorded an impairment charge
of $81,428,000; $51,921,000 for intangible assets and $29,507,000 for
tangible capital assets. The fair value of the intangible assets was
determined using a discounted cash flow methodology and the fair value of
tangible capital assets was based on a value in continued use, taking
into account utilization levels. During the third quarter of 2006 the
Company also tested the recoverability of the goodwill associated with
Puerto Rico operations using a discounted cash flow methodology, and
recorded an impairment charge of $172,477,000 representing the full value
of the Puerto Rico goodwill.
During the third quarter of 2006 the Company, as part of its ongoing
review of long term investments, concluded that its investment in the
shares of a drug technology company which was accounted for on the cost
basis had an other than temporary decline and wrote down its value by
$756,000 to its market value as of July 31, 2006.
A summary of the asset impairment charges is as follows:
Twelve months ended October 31,
-------------------------------------------------------------------------
2007 2006
$ $
-------------------------------------------------------------------------
Intangible asset impairment 26,043 51,921
Tangible capital asset impairment 22,537 29,507
Goodwill impairment - 172,477
Other investment impairment - 756
-------------------------------------------------------------------------
48,580 254,661
-------------------------------------------------------------------------
5. Discontinued operations and assets held for sale
On April 17, 2007 the Company announced that as part of its strategy to
focus on developing and manufacturing prescription pharmaceutical
products and to improve the Company's profitability, it plans to
restructure its current network of six pharmaceutical manufacturing
facilities in Canada.
In connection with this initiative, on December 6, 2007 the Company
announced that it had entered into a definitive agreement to sell its
Niagara-Burlington operations focused on the manufacturing of OTC
products to Pharmetics Inc. See the subsequent events note 14.
The Company also plans to close its York Mills, Toronto facility and
transfer substantially all commercial production and development services
to its site in Whitby and sell the land and buildings. The process of
transferring production to other facilities is expected to be completed
by the first half of fiscal 2009.
The results of the Niagara-Burlington operations have been reported as
discontinued operations and prior period amounts have been reclassified
to conform to the current period presentation. During the third quarter
of 2007 the Company recorded an impairment charge of $13,029,000 to write
down the carrying value of Niagara-Burlington operations long-lived
assets to their fair value less estimated disposition costs. In the
fourth quarter of 2007 the Company recorded an adjustment of $564,000 to
reduce the impairment charge to reflect the Company's revised estimate of
the fair value of the long-lived assets.
The results of discontinued operations for the three and twelve months
ended October 31, 2007 and 2006 are as follows:
Three months Twelve months
ended October 31, ended October 31,
-------------------------------------------------------------------------
2007 2006 2007 2006
$ $ $ $
-------------------------------------------------------------------------
Revenues 6,815 9,365 35,244 37,493
Operating expenses 6,281 8,562 32,475 34,580
-------------------------------------
Earnings before the following: 534 803 2,769 2,913
-------------------------------------
(as a % of revenues) 7.8% 8.6% 7.9% 7.8%
Asset impairment charge (564) - 12,465 -
Repositioning expenses (recovery) (430) 789 (397) 789
Depreciation and amortization - 268 844 1,112
-------------------------------------
Earnings (loss) before
income taxes 1,528 (254) (10,143) 1,012
Provision for income taxes - - - 443
-------------------------------------------------------------------------
Net earnings (loss) for the period 1,528 (254) (10,143) 569
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Assets held for sale and the related liabilities include the Niagara-
Burlington Operations and the land and buildings at York Mills. In
accordance with Section 3475 of the CICA Handbook, long-lived assets held
for sale are measured at the lower of their carrying amount or fair value
less cost to sell. Assets held for sale and the related liabilities, as
at October 31, are as follows:
As at October 31,
-------------------------------------------------------------------------
2007 2006
$ $
-------------------------------------------------------------------------
Current Assets
Accounts receivable 4,376 4,251
Inventories 5,307 3,905
Prepaid expenses and other 160 185
------------------
Total current assets 9,843 8,341
------------------
Capital assets 16,662 26,723
Current Liabilities
Accounts payable and accrued liabilities 3,174 2,527
Other long-term liabilities 1,523 1,416
-------------------------------------------------------------------------
6. Stock-based compensation
The Company has an incentive stock option plan. Persons eligible to
participate in the plan are directors, officers, and key employees of the
Company and its subsidiaries or any other person engaged to provide
ongoing management or consulting services to Patheon. The plan provides
that the maximum number of shares that may be issued under the plan is
7.5% of the issued and outstanding restricted voting shares of the
Company at any point in time. As of October 31, 2007, the total number of
restricted voting shares listed and reserved at the TSX for issuance
under the plan was 6,850,427 of which there are stock options outstanding
to purchase 3,857,916 shares under the plan. The exercise price of
restricted voting shares subject to an option is determined at the time
of grant and the price cannot be less than the weighted average market
price of the restricted voting shares of Patheon on the Toronto Stock
Exchange during the two trading days immediately preceding the grant
date. Options generally expire 10 years after the grant date and are also
subject to early expiry in the event of death, resignation, dismissal or
retirement of an optionee. Options vest over one to three years, with one-
third vesting on each of the first, second and third anniversaries of the
grant date for those vesting over three years.
For the purposes of calculating the stock-based compensation expense, the
fair value of stock options is estimated at the date of the grant using
the Black-Scholes option pricing model and the cost is amortized over the
vesting period. No options were granted in the fourth quarter of 2007 and
2006. The weighted average fair value of 100,000 options granted for the
twelve months ended October 31, 2007 was $1.92. The weighted average fair
value for the stock options granted for the twelve months ended
October 31, 2006 was $1.73. The following assumptions were used in
arriving at the fair value of options issued during the twelve months
ended October 31, 2007:
Risk free interest rate 4.2%
Expected volatility 42%
Expected weighted average life of options 6 years
Expected dividend yield 0%
Stock-based compensation expense recorded in the three months ended
October 31, 2007 was $52,000 (2006 - $3,000) for options granted on or
after November 1, 2003. Stock-based compensation expense recorded in the
twelve months ended October 31, 2007 was $220,000 (2006 - $928,000) for
options granted on or after November 1, 2003.
7. Repositioning expenses
The Company has incurred a number of expenses associated with its
performance enhancement program, which is intended to identify
operational improvements and cost reduction initiatives. The related
expenses include costs associated with a reduction in the work force,
project management costs and consulting fees from external specialists
who are assisting in identifying operational improvements.
During 2007 the Company also incurred professional fees and other costs
in connection with its review of strategic and financial alternatives.
The following is a summary of expenses associated with these initiatives
(collectively "repositioning expenses") for the three and twelve months
ended October 31:
Three months ended Twelve months ended
October 31, October 31,
-------------------------------------------------------------------------
2007 2006 2007 2006
$ $ $ $
-------------------------------------------------------------------------
Performance enhancement
program:
- Employee-related expenses 6,111 8,821 8,938 8,821
- Consulting, professional
and project management
costs 603 1,193 3,507 1,193
Strategic alternatives review - 2,984 3,355 2,984
-------------------------------------------------------------------------
6,714 12,998 15,800 12,998
-------------------------------------------------------------------------
-------------------------------------------------------------------------
As at October 31, 2007, $6,048,000 of the repositioning expenses are
unpaid and are recorded in accounts payable and accrued liabilities.
Repositioning expenses paid during the three months and twelve months
ended October 31, 2007 amounted to $2,276,000 and $18,998,000
respectively.
8. Other information
Foreign exchange
During the three months ended October 31, 2007, the foreign exchange gain
on operating exposures, (including benefits from cash flow hedges and the
revaluation of all foreign currency denominated assets and liabilities,
other than those liabilities designated as a hedge against foreign
currency denominated net investments) recorded in operating expenses was
$5,828,000 (2006 - $941,000). During the twelve months ended October 31,
2007, the foreign exchange gain on operating exposures was $8,921,000
(2006 - $817,000).
During the twelve months ended October 31, 2007, the Company recorded a
foreign exchange loss of $858,000 in connection with a change in the
Company's internal capital structure, which resulted in the recognition
of foreign exchange translation losses previously recorded in accumulated
other comprehensive income.
Employee future benefits
The employee future benefit expense in connection with defined benefit
pension plans and other post retirement benefit plans for the three
months ended October 31, 2007 was a recovery of $2,872,000 (2006 expense
- $2,806,000). For the twelve months ended October 31, 2007 the employee
future benefit expense was $1,752,000 (2006 - $6,214,000). The employee
future benefit expense for the three months and twelve months ended
October 31, 2007 includes a curtailment gain of $4,292,000 in connection
with a decision made to phase out benefits under one of the Company's
post retirement benefit plans.
9. Financial instruments
The Company utilizes financial instruments to manage the risk associated
with fluctuations in foreign exchange and interest rates. The Company
formally documents all relationships between hedging instruments and
hedged items, as well as its risk management objective and strategy for
undertaking various hedge transactions.
As at October 31, 2007 the Company's Canadian operations had entered into
foreign exchange forward contracts to sell an aggregate amount of
US$34,172,000. These contracts hedge the Canadian operations expected
exposure to U.S. dollar denominated cash flows and mature at the latest
on April 21, 2008, at an exchange rate of $1.0535 Canadian. The
mark-to-market value on these financial instruments as at
October 31, 2007 was an unrealized gain of $4,052,000 which has been
recorded in accumulated other comprehensive income in shareholders'
equity.
As at October 31, 2007 the Company's Canadian operations had entered into
a foreign exchange contract to purchase US$45,000,000. The contract
matures on January 28, 2010, at an exchange rate of $1.0015 Canadian. The
contract hedges the Canadian operations net US dollar balance sheet
exposure. The mark-to-market value of this contract was a loss of
$2,699,000, which has been recorded in operating expenses.
As at October 31, 2007 the Company has designated $141.6 million of
U.S. dollar denominated debt as a hedge against its net investment in its
subsidiaries in the U.S.A. and Puerto Rico. The exchange gains and losses
arising from this debt, from the date so designated, are recorded in
accumulated other comprehensive income in shareholders' equity.
The Company has entered into interest rate swap contracts to convert all
of the interest costs on its senior secured term loan from a floating to
a fixed rate of interest until March 30, 2010. The mark-to-market value
of these financial instruments at October 31, 2007 was an unrealized loss
of $2,593,000 which has been recorded in accumulated other comprehensive
income in shareholders' equity.
10. Refinancing
Convertible Preferred Shares
----------------------------
On April 27, 2007 JLL Partners, through its investment vehicle, JLL
Patheon Holdings, LLC, purchased 150,000 convertible preferred shares of
Patheon for $150 million. Until October 27, 2009, no cash dividends will
be paid on the preferred shares, but the liquidation preference and
conversion rate will increase on a quarterly basis by 2.125%. After
October 27, 2009, these increases in the liquidation preference and
conversion rate will continue until the maturity or prior conversion,
unless the Company elects to pay a cash dividend for any applicable
quarter, in which case the Company will pay a cash dividend for such
quarter based on an annual dividend rate of 8.5% on the aggregate
liquidation preference of the convertible preferred shares.
Each convertible preferred share is convertible into 218.7154 restricted
voting shares, as adjusted for any non-cash dividends noted above, at any
time at the holder's option. The Company is entitled to require the
holder to convert into restricted voting shares if, at any time after
October 27, 2009, the market price of the restricted voting shares on the
Toronto Stock Exchange exceeds a price equivalent to US$7.87 for a period
of at least 60 days.
If not previously converted, the Company is required to redeem the
convertible preferred shares for cash on April 27, 2017 at a price equal
to the aggregate liquidation preference of the convertible preferred
shares, plus accrued and unpaid dividends thereon. The Company is also
required to redeem the convertible preferred shares upon the occurrence
of a change of control of Patheon at a price equal to the greater of the
aggregate liquidation preference of the convertible preferred shares,
plus accrued and unpaid dividends thereon, or the price per share paid to
holders of restricted voting shares in the change of control transaction,
multiplied by the number of restricted voting shares into which the
convertible preferred shares are then convertible.
On issuance, the fair value of the debt component of the preferred shares
was $132,862,000. The remainder of the proceeds attributable to
shareholders' equity was $15,925,000, net of apportioned transaction
costs of $1,213,000.
Senior Secured Credit Facilities
--------------------------------
On April 27, 2007, the Company completed new credit facilities in the
aggregate amount of $225 million, comprising a seven-year $150 million
senior secured term loan and a five-year $75 million asset based
revolving credit facility. The Company is required to make quarterly
installment payments of $375,000 on the term loan facility, along with
additional mandatory repayments based on certain excess cash flow
measures. Interest on the facilities is at floating rates based on LIBOR,
US prime, or the federal funds effective rate, plus applicable margins.
The facilities are secured by substantially all of the assets of the
Company's operations in Canada, U.S.A., Puerto Rico and the U.K. and the
Company's investments in the shares of all other operating subsidiaries.
Net proceeds from the issue of the convertible preferred shares and the
senior secured term loan facility were used to repay the Company's
obligations under its existing North American and U.K. credit facilities.
11. Refinancing expenses and write-off of deferred financing costs
During the second quarter of 2007 the Company incurred expenses of
$13,471,000 in connection with its refinancing activities. The expenses
consist of transaction costs relating to the new credit facilities, costs
allocated to the debt portion of the convertible preferred shares and
prepayment charges in connection with cancellation of certain of the
Company's U.K. debt facilities.
During the first quarter of 2006, the Company incurred charges of
$1,643,000 in connection with the cancellation and prepayment of certain
of its North American credit facilities. The Company also wrote off
$6,332,000 in related deferred financing costs.
12. Other comprehensive income
The amounts disclosed in other comprehensive income have been recorded
net of income taxes and take into account valuation reserves for future
income taxes in the Company's Canadian operations. For the three and
twelve months ended October 31, 2007 there is no tax expense in
connection with the change in foreign currency gains on investments in
subsidiaries, net of hedging activities. Foreign currency losses on
investments in subsidiaries, net of hedging activities reclassified to
the consolidated statement of earnings (loss) are net of an income tax
benefit of $1,935,000 for the twelve months ended October 31, 2007. The
change in value of derivatives designated as foreign currency and
interest rate cash flow hedges have been reported net of a tax benefit of
$257,000 and $373,000 for the three and twelve months ended October 31,
2007, respectively. The gains on foreign currency and interest rate cash
flow hedges reclassified to the consolidated statement of earnings (loss)
are net of an income tax benefit of $343,000 for the twelve months ended
October 31, 2007.
13. Related party transactions
Revenues from companies controlled by a director and significant
shareholder of the Company were in the amount of $66,000 and $473,000 for
the three and twelve months ended October 31, 2007, respectively. These
transactions were conducted in the normal course of business and are
recorded at the exchanged amount which management believes to be at fair
value. Accounts receivable at October 31, 2007 includes a balance of
$392,000.
At October 31, 2007 the Company has an investment of $739,000
representing an 18% interest in two Italian companies (collectively
referred to as "BSP Pharmaceuticals") whose largest investor is an
officer of the Company. These newly formed companies will specialize in
the manufacturing of cytotoxic pharmaceutical products.
The Company has accrued management fees owing to it under a management
services agreement with BSP Pharmaceuticals of $484,000 and $1,593,000
for the three months and twelve months end October 31, 2007,
respectively. These fees will be invoiced to BSP Pharmaceuticals once it
has finalized all of its bank financing. These services were conducted in
the normal course of business and are recorded at the exchanged amounts
which management believes to be at fair value.
In connection with certain of BSP Pharmaceuticals' bank financing, the
Company has made commitments that it will not dispose of its interest in
BSP Pharmaceuticals prior to January 1, 2011.
14. Subsequent events
On December 6, 2007 the Company announced that it had entered into a
definitive agreement to sell its Niagara-Burlington commercial
manufacturing business to Pharmetics Inc. Under the terms of the
agreement Pharmetics will acquire the assets, including equipment
facilities and land at the Company's facilities in Fort Erie and
Burlington (Gateway Drive). Pharmetics will provide employment to all of
the commercial manufacturing employees at the two sites and, subject to
assignment of third party contracts, will continue to manufacture and
supply all of the products currently manufactured at these sites.
The transaction is expected to be completed on or about January 31, 2008,
subject to closing conditions including regulatory approvals, the
assignment of client and other contracts and the completion of financing
arrangements by the purchaser. The purchase price for the business is
CAD$5.75 million plus working capital, subject to adjustments.
On December 14, 2007 the Company announced that as a result of its review
of the Puerto Rico operations, with a focus on restructuring the
operations, eliminating operating losses and developing a long-term plan
for the business, it has decided to retain and continue to streamline its
facilities in Caguas and Manati and divest its facility in Carolina.
Revenues for the three months and twelve months ended October 31, 2007
for the Carolina operations were $5.0 million and $42.9 million
respectively. The Carolina operations reported a loss before
repositioning expenses, asset impairment charge, depreciation and
amortization, foreign exchange losses reclassified from other
comprehensive income, interest, refinancing charges, write-off of
deferred financing costs and income taxes for the three month period
ended October 31, 2007 of $2.5 million and a profit of $6.1 million for
the twelve month period ended October 31, 2007.
15. Comparative amounts
Certain comparative amounts have been reclassified to conform to the
current period presentation.
Patheon Inc.
Management's Discussion and Analysis of Financial Condition and
Results of Operations
The following management discussion and analysis of financial condition and results of operations ("MD&A") of Patheon Inc. ("Patheon" or "the Company") for the three-month and twelve-month periods ended October 31, 2007 and 2006 should be read in conjunction with the Company's consolidated financial statements and related notes contained in this interim report. All amounts are in US dollars unless otherwise indicated. This MD&A is dated as of December 14, 2007.
The purpose of this 2007 fourth quarter report is to provide an update to the information contained in the Company's Management's Discussion and Analysis section of the Company's 2006 Annual Report, which contains a more comprehensive discussion of the Company's strategy, capabilities to deliver results, risks and key performance indicators. Management assumes that the reader of this document has access to the MD&A section of the Company's 2006 Annual Report. This document and other information can be downloaded in portable document format (PDF) from the Company's web site at www.patheon.com or from the SEDAR web site for Canadian regulatory filings at www.sedar.com. To request a printed copy, the reader may also contact Patheon's transfer agent, Computershare Investor Services Inc., at 1-800-564-6253 or via email at service@computershare.com, or Patheon at www.patheon.com.
Use of Non-GAAP Financial Measures
Except as otherwise indicated, references in this MD&A to "EBITDA before repositioning expenses" are to earnings from continuing operations before repositioning expenses, asset impairment charges, depreciation and amortization, foreign exchange losses reclassified from other comprehensive income, interest, refinancing expenses, write-off of deferred financing costs, and income taxes. "EBITDA margin before repositioning expenses" is EBITDA before repositioning expenses divided by revenues. EBITDA before repositioning expenses and EBITDA margin before repositioning expenses are measures of earnings or earnings margin not recognized by generally accepted accounting principles in Canada ("Canadian GAAP"). Since each of these measures is a non- GAAP measure that does not have a standardized meaning, it may not be comparable to similar measures presented by other issuers. Prospective investors are cautioned that these, and other non-GAAP measures should not be construed as alternatives to net earnings determined in accordance with Canadian GAAP as indicators of performance. The Company has included these measures because it believes that this information is used by certain investors to assess the financial performance of the Company, in particular the operating earnings before non-cash charges and large and non-recurring costs.
Overview of Patheon
Patheon is focused exclusively on providing commercial manufacturing and pharmaceutical development services to pharmaceutical, biotechnology and specialty pharmaceutical companies located primarily in North America, Europe and Japan. Patheon serves its international clientele from its operating facilities in North America (including Puerto Rico) and Europe.
Patheon commercially manufactures prescription ("Rx") and over-the- counter ("OTC") products in solid, semi-solid and liquid dosage forms. Conventional dosage forms include compressed tablets, hard-shell capsules, powders, ointments, creams, gels, syrups, suspensions, solutions and suppositories. Sterile dosage forms include liquids and powders filled in ampoules, vials, bottles or pre-filled syringes. Sterile lyophilized products are also manufactured in both vials and ampoules.
Patheon provides manufacturing services for a broad range of products in many dosage forms and packaging formats in accordance with client specifications. Depending on the particular client, Patheon may be responsible for most or all aspects of the manufacturing and packaging process, from sourcing excipient raw materials and packaging components to delivering the finished product in consumer-ready form to the client. Typically, Patheon's clients supply the active pharmaceutical ingredients ("API") used in the production process.
The pharmaceutical development services provided by Patheon include most of the pharmaceutical development services typically required by companies conducting clinical trials and preparing for full-scale commercial production of a new drug.
At October 31, 2007, there were a total of 199 client products in Patheon's pharmaceutical development services ("PDS") pipeline, including nine drug candidates at the New Drug Application ("NDA") stage. This compares with a total of 171 client products a year ago, of which five were at the NDA stage. During the fourth quarter of 2007, no products developed on behalf of clients were launched from the Company's facilities.
Vision and Strategy
Patheon's vision is to be the leader in pharmaceutical contract manufacturing. Patheon strives to be the preferred manufacturing and pharmaceutical development services partner to the global pharmaceutical industry. Patheon's strategy is focused on providing "best-in-class" manufacturing and development services effectively balancing high product quality and reliability of supply with cost.
Patheon expects that stronger manufacturing and development relationships will continue to emerge between pharmaceutical companies and service companies as the pharmaceutical industry continues to re-evaluate its internal manufacturing capabilities and streamlines its external service-provider network. The Company is using its position as a comprehensive provider of commercial manufacturing and development services to establish and maintain long-term, strategic relationships with clients on a global basis.
Prior to 2006, a key aspect of Patheon's strategy was a plan to expand capacity, expertise and capabilities through acquisitions, positioning the Company to be the preferred manufacturing services partner to the pharmaceutical industry. This led to the acquisition of several pharmaceutical manufacturing facilities and the entry into long-term manufacturing relationships in conjunction with certain of these acquisitions. More recently Patheon has focused on growing the business internally by expanding the level of business from existing clients, attracting new clients, and entering into commercial manufacturing agreements for newly approved products for which the Company has provided development services.
In implementing its strategy, the Company will continue to maximize capacity utilization and improve efficiency, broaden its services to include other specialized manufacturing capabilities and seek to increase the percentage of more profitable products manufactured at its facilities. In addition, the Company will seek to expand its PDS capabilities in North America and Europe to better serve the needs of the global pharmaceutical industry. Pharmaceutical development services are an important source of new business for commercial manufacturing of prescription pharmaceuticals.
Key Performance Drivers
In Patheon's 2006 Annual Report, several key performance drivers for the Company were identified: (i) generating higher quality revenues by increasing the percentage of higher margin Rx manufacturing and pharmaceutical development services; (ii) improving capacity utilization at the Company's sites which have a large fixed-cost base in the short term; (iii) improving operating efficiencies through a performance enhancement program with initiatives focused on a global procurement program, a workforce reduction program and a manufacturing efficiency review process; and (iv) mitigating the impact of changes in the foreign exchange trading relationship between the Canadian and U.S. dollar, since the Company's contracts in North America are primarily denominated in U.S. dollars, but the operating expenses of its Canadian sites are primarily denominated in Canadian dollars. An update on our interim performance relating to these key issues is provided in the sections below entitled "Recent Developments" and "Results of Operations".
Recent Developments
Financing Arrangements and Strategic Alternatives
On September 11, 2006 the Company announced that its Board of Directors had established a special committee to evaluate a range of strategic and financial alternatives for the Company. As a result of this review, on April 27, 2007 JLL Partners, through its investment vehicle, JLL Patheon Holdings, LLC ("JLL Partners") purchased $150 million of convertible preferred shares of the Company through a private placement. On April 27, 2007 the Company also completed new credit facilities in the aggregate amount of $225 million, comprising a seven-year $150 million term loan and a five-year $75 million revolving facility.
The net proceeds from the JLL Partners investment and the seven-year term loan were used to repay the Company's obligations under its existing North American and U.K. credit facilities.
Restructuring the Canadian Site Network
On April 17, 2007 the Company announced that as part of its strategy to focus on developing and manufacturing Rx pharmaceutical products and to improve the Company's profitability, it plans to restructure its current network of six pharmaceutical manufacturing facilities in Canada.
In connection with this initiative, on December 6, 2007 the Company announced that it had entered into a definitive agreement to sell its Niagara- Burlington commercial manufacturing business to Pharmetics Inc. Under the terms of the agreement Pharmetics will acquire the assets, including equipment facilities and land at the Company's facilities in Fort Erie and Burlington (Gateway Drive). Pharmetics will provide employment to all of the commercial manufacturing employees at the two sites and, subject to assignment of third party contracts, will continue to manufacture and supply all of the products currently manufactured at these sites.
The transaction is expected to be completed on or about January 31, 2008, subject to closing conditions including regulatory approvals, the assignment of client and other contracts and the completion of financing arrangements by the purchaser. The purchase price for the business is CAD$5.75 million plus working capital, subject to adjustments.
The Company also plans to close its York Mills, Toronto facility and transfer substantially all commercial production and development services to its site in Whitby and sell the land and buildings. The process of transferring production to other facilities is expected to be completed by the first half of fiscal 2009.
The assets and the related liabilities of the Niagara-Burlington Operations, along with the York Mills real estate have been classified as held for sale on the balance sheet in the consolidated financial statements.
Restructuring the Puerto Rico Operations
On December 14, 2007 the Company announced that as a result of its comprehensive review of the Puerto Rico operations, with a focus on restructuring the operations, eliminating operating losses and developing a long-term plan for the business it has decided to retain and continue to streamline its facilities in Caguas and Manati, and divest its facility in Carolina, Puerto Rico.
The Carolina site is a 230,000-square-foot facility, with approximately 200 employees, that specializes in the manufacture of oral cephalosporin solid dosage forms, including tablets, capsules and powders for suspension. It currently manufactures four products on behalf of six clients.
The Company has concluded that Carolina, a high-quality site with specialized capabilities and expertise, would be of greater strategic value to another company with a focus on manufacturing oral cephalosporins. The divestiture will allow the Company to focus on improving operating performance and growing the business at the Caguas and Manati facilities.
It is anticipated that the purchaser will assume responsibility for the staff at the facility, and contracts with third parties subject to their approval. Patheon has retained an advisor to manage the sale of the Carolina site.
Results of Operations
The results of operations of the Niagara-Burlington Operations have been segregated and presented separately as discontinued operations. All comparative amounts have been reclassified to conform to the current period presentation.
Revenues by Geographic Region and Service Activity
Three months ended Twelve months ended
U.S.$ '000 October 31, October 31,
% %
2007 2006 Change 2007 2006 Change
------------------------ ------------------------
North America
-------------
Commercial
Manufacturing
Prescription 56,543 77,388 -27% 270,515 309,379 -13%
Over-the-counter 14,564 11,411 28% 43,076 66,327 -35%
------------------------ ------------------------
71,107 88,799 -20% 313,591 375,706 -17%
Development Services 23,151 20,652 12% 84,532 74,986 13%
------------------------ ------------------------
94,258 109,451 -14% 398,123 450,692 -12%
------------------------ ------------------------
Europe
------
Commercial
Manufacturing
Prescription 62,683 47,204 33% 243,554 197,332 23%
Over-the-counter 291 1,170 -75% 3,473 3,646 -5%
------------------------ ------------------------
62,974 48,374 30% 247,027 200,978 23%
Development Services 9,560 7,925 21% 31,924 22,989 39%
------------------------ ------------------------
72,534 56,299 29% 278,951 223,967 25%
------------------------ ------------------------
TOTAL
-----
Commercial
Manufacturing
Prescription 119,226 124,592 -4% 514,069 506,711 1%
Over-the-counter 14,855 12,581 18% 46,549 69,973 -33%
------------------------ ------------------------
134,081 137,173 -2% 560,618 576,684 -3%
Development Services 32,711 28,577 14% 116,456 97,975 19%
------------------------ ------------------------
CONSOLIDATED REVENUES 166,792 165,750 1% 677,074 674,659 0%
------------------------ ------------------------
------------------------ ------------------------
Three Months Ended October 31, 2007 Compared with Three Months Ended
October 31, 2006
Revenues
Consolidated revenues from continuing operations for the three-month period ended October 31, 2007 increased 1%, or $1.0 million, to $166.8 million from $165.8 million in the same period in 2006. In the fourth quarter, revenues increased for OTC manufacturing and PDS, but decreased for Rx manufacturing. On a consolidated basis, compared with the fourth quarter of 2006, OTC and PDS revenues increased by 18% and 14%, respectively, and Rx revenues declined by 4%.
For the three-month period ended October 31, 2007 revenues excluding the Puerto Rico operations were $151.9 million, compared with $131.9 million in the same period last year.
Prescription manufacturing and development services represented 91% of revenues, compared with 92% for the comparable period in 2006. The decline reflects a significant decrease in Rx manufacturing volumes in Puerto Rico.
Geographically, in North America, revenues declined in the fourth quarter by $15.2 million or 14% over the same period a year ago. The decrease reflects a significant decline in Rx revenues in the Carolina and Caguas facilities in Puerto Rico as a result of lower revenues for Omnicef(R), which was impacted by the launch of generic competitive products in May of 2007, the elimination of manufacturing of Zocor(R) and lower volumes of Levothyroxine sodium, where the client has suffered a significant decline in market share. Rx revenues were also slightly lower in Canada, in part due to delays in the availability of active pharmaceutical ingredients. These declines were offset in part by higher PDS and OTC manufacturing volumes in the Canadian and Cincinnati operations.
In Europe, revenues for the fourth quarter of 2007 increased by $16.2 million or 29% over the same period of 2006. The year-over-year increase reflects higher Rx manufacturing revenues from operations in France and Italy, reflecting the continuing benefits from two carve out initiatives, where the Company is manufacturing a range of products for two clients that have closed down facilities within their own manufacturing network. In Swindon, U.K., PDS revenues showed continued growth, but commercial manufacturing volumes were lower as a result of production delays, which are expected to be recovered during the first half of 2008. The Euro strengthened approximately 9% and U.K. sterling strengthened approximately 7% against the U.S. dollar relative to the same period last year, increasing reported revenues by approximately $5.8 million. Had European currencies remained constant to the rates of the prior year, European revenues would have been 18% higher than the same period in 2006.
Operating Expenses
Operating expenses comprise processing costs (principally materials, employee and other site-related costs), marketing, sales, service, corporate support, administrative expenses and foreign exchange gains and losses. In the fourth quarter of 2007, operating expenses were $145.6 million, being $1.4 million lower than the same period a year ago. Operating expenses were reduced in the fourth quarter by net foreign exchange gains of $5.8 million. The foreign exchange gains have arisen from the revaluation of US dollar denominated debt in Canada and benefits from the Company's cash flow hedging program, offset in part by losses arising from the revaluation of foreign denominated working capital. Operating expenses were further reduced in the fourth quarter as a result of an actuarial gain of $4.3 million arising from a decision to phase out certain post retirement benefits in the Canadian operations. Ongoing expenses were impacted by the strengthening of European and Canadian currencies relative to the U.S. dollar. Operating expenses as a percentage of revenues were 87.3%, compared with 88.7% in the same period a year ago.
EBITDA Before Repositioning Expenses and EBITDA Margin Before
Repositioning Expenses
On a consolidated basis in the fourth quarter of 2007, EBITDA before repositioning expenses, representing earnings from continuing operations before repositioning expenses, asset impairment charge, depreciation and amortization, foreign exchange losses reclassified from other comprehensive income, interest, refinancing expenses, write-off of deferred financing costs, and income taxes was $21.2 million, compared with $18.8 million in the same period a year ago. EBITDA margin before repositioning expenses was 12.7% in the three-month period, compared with 11.3% in the same period a year ago.
For the three-month period ended October 31, 2007 EBITDA before repositioning expenses excluding the Puerto Rico operations was $30.4 million, compared with $18.5 million in the same period last year. This represents an EBITDA margin before repositioning expenses of 20.0% in the three month period, compared with 14.0% in the same period last year.
In Canada, EBITDA before repositioning expenses from the commercial operations was $6.9 million in the fourth quarter of 2007, being $1.7 million higher than the same period last year. This improvement was achieved despite lower production volumes and includes a significant portion of the actuarial gains arising from a change in the Company's post retirement benefit plans. EBITDA before repositioning expenses was not significantly impacted by foreign exchange in the fourth quarter of 2007, as the negative earnings impact of the strengthening Canadian dollar relative to the U.S. dollar, was offset by gains from the Company's foreign exchange cash flow hedging program.
In the U.S.A. (including Puerto Rico), EBITDA before repositioning expenses for the commercial operations was a loss of $4.5 million in the fourth quarter of 2007, compared with a profit of $5.7 million in the same period last year. The significant deterioration in earnings principally reflects a reduction in Rx manufacturing volumes in the Carolina and Caguas facilities in Puerto Rico.
In Europe, EBITDA before repositioning expenses from the commercial operations was $3.8 million in the fourth quarter of 2007, being $0.3 million lower than the same period a year ago. The benefits of higher volumes were offset by additional variable compensation costs, incremental costs associated with production delays in Swindon, UK and foreign exchange losses. The strengthening European currencies relative to the US dollar compared with the same period last year had the impact of increasing EBITDA before repositioning expenses by approximately $0.3 million.
EBITDA before repositioning expenses from the global PDS operations was $9.4 million in the fourth quarter of 2007, being $3.2 million higher than the same period in 2006. The increase reflects revenue growth across the network.
Corporate costs in the fourth quarter of 2007 reflected a net recovery of $5.5 million, compared with costs of $2.6 million in the same period last year. This reported gain resulted from foreign exchange gains of $7.5 million arising from the revaluation of US dollar denominated debt held in the Canadian legal entity. In October 2007 the Company hedged its net US dollar balance sheet exposure, which will reduce future volatility.
Repositioning Expenses
During the fourth quarter of 2007 the Company incurred $6.7 million of expenses in connection with its performance enhancement program. The expenses were associated with cost saving initiatives being undertaken in the Caguas and Carolina facilities in Puerto Rico and in the restructuring of the Canadian site network.
Depreciation and Amortization Expense
Depreciation and amortization expense was $10.4 million in the fourth quarter of 2007, compared with $9.7 million in the fourth quarter of 2006. The increase reflects the impact of the strengthening European and Canadian currencies relative to the US dollar, offset in part by lower depreciation charges in Carolina as a result of the asset impairment charge booked in the third quarter of 2007.
Amortization of Intangible Assets
Amortization of intangible assets was $1.1 million in the fourth quarter of 2007, compared with $2.2 million for the fourth quarter of 2006. The amortization of intangible assets relates to the Puerto Rico operations. The charge is lower than for the same period last year due to the impact of the impairment charge booked in the third quarter of 2007.
Interest Expense and Amortization of Deferred Financing Costs
Interest expense for the fourth quarter of 2007 was $7.5 million, compared with $6.2 million in the fourth quarter of 2006. The increase in interest costs principally reflects the impact of the new financing arrangements that were put in place on April 27, 2007 and includes a non-cash accretive interest charge of $3.6 million in respect of the debt component of the convertible preferred shares.
Effective November 1, 2006, the Company adopted CICA Accounting Standard Section 3855 for the accounting of financial instruments, including its policy on deferring costs of obtaining bank and other debt financing (see "Critical Accounting Policies and Estimates"). As a result, amounts that in prior periods were recorded as amortization of deferred financing costs are now recorded in interest expense.
Loss Before Income Taxes from Continuing Operations
The Company reported a loss before income taxes of $4.5 million in the fourth quarter of 2007, compared with a loss of $12.7 million in the same period a year ago.
Income Taxes
The Company recorded an income tax charge of $4.6 million in the fourth quarter of 2007, compared with a charge of $9.5 million in the same period last year. The income tax charge in 2007 principally reflects operating losses in Puerto Rico, where the tax benefits recognized were minimal, compounded by high tax rates in Italy where the Company reported significant profits. Offsetting these was the benefit of pre tax earnings in Canada, which were sheltered by the draw down of prior period unrecognized losses. In 2006 the income tax expense included a valuation reserve charge of $6.4 million against future tax asset balances in the Canadian operations.
Loss and Loss Per Share from Continuing Operations
The Company recorded a loss from continuing operations in the fourth quarter of 2007 of $9.1 million, compared with a loss of $22.2 million in the same period last year. The loss per share was 9.9 cents, compared with a loss of 23.8 cents per share a year earlier. The loss in 2007 included after tax repositioning expenses of $6.8 million or 7.3 cents per share. The loss in 2006 included after tax asset repositioning expenses of $12.2 million or 13.2 cents per share.
Because the Company reported a loss in the fourth quarter of 2007 and 2006, there is no impact of dilution.
Earnings (Loss) and Earnings (Loss) Per Share from Discontinued
Operations
Discontinued operations include the results of the Niagara-Burlington Operations. Financial details of the operating activities are disclosed in note 5 in the interim consolidated financial statements. Earnings from discontinued operations in the fourth quarter of 2007 were $1.5 million, or 1.7 cents compared with a loss of $0.3 million or 0.3 cents in the same period last year. The improvement reflects the reversal of repositioning expense accruals in the fourth quarter, compared with a charge in the same period last year. In the fourth quarter of 2007 the Company also recorded a $0.6 million reduction to the asset impairment charge that had been booked in the third quarter of 2007, to reflect the Company's revised estimate of the fair value of the long-lived assets.
Twelve Months Ended October 31, 2007 Compared with Twelve Months Ended
October 31, 2006
Revenues
Consolidated revenues from continuing operations for the twelve-month period ended October 31, 2007 increased $2.4 million to $677.1 million from $674.7 million in the same period in 2006. Rx manufacturing and PDS revenues grew by 1% and 19%, respectively, while OTC manufacturing revenues declined by 33%.
For the twelve-month period ended October 31, 2007 revenues excluding the Puerto Rico operations were $577.3 million, compared with $544.9 million in the same period last year.
Prescription manufacturing and development services represented 93% of revenues, compared with 90% for the comparable period in 2006. This improvement is consistent with one of the Company's key performance drivers of increasing the percentage of higher margin Rx and PDS business.
Geographically, in North America, revenues for the twelve months ended October 31, 2007 declined by $52.5 million or 12% over the same period a year ago. The decline reflects a significant reduction in OTC volumes in the Whitby and Cincinnati operations as certain clients have repatriated products back to their own manufacturing network. Rx volumes declined in Caguas and Carolina, Puerto Rico as a result of lower production of Zocor(R), Levothyroxine sodium and Omnicef(R). Rx revenues were also lower in Canada principally as a result of lower volumes for a product where in 2006 the Company's client was building trade inventory levels for a newly launched product. The declines in commercial manufacturing revenues were offset in part by an increase in PDS revenues in Canada and Cincinnati.
In Europe, revenues for the twelve months ended October 31, 2007 were $55.0 million or 25% higher than the same period of 2006. The year-over-year increase in revenues reflects higher Rx manufacturing revenues from operations in Italy and France arising from the continuing benefits from two carve out initiatives, where the Company is manufacturing a range of products for two clients that have closed down facilities within their own manufacturing network. In Swindon, U.K. PDS operations also continued to show further increases in volumes. These gains were offset in part by lower pre-launch commercial revenues for the cephalosporin lyophilization services and production delays during the fourth quarter. The Euro and U.K. sterling strengthened approximately 9% and 10%, respectively, against the U.S. dollar relative to the same period last year, increasing reported revenues by approximately $22.9 million. Had European currencies remained constant to the rates of the prior year, European revenues would have been 14% higher than the same period in 2006.
Operating Expenses
Operating expenses comprise processing costs (principally materials, employee and other site-related costs), marketing, sales, service, corporate support, administrative expenses and foreign exchange gains and losses. In the twelve-month period ended October 31, 2007 operating expenses were $586.8 million, compared with $603.8 million in the same period a year ago, a decline of 3%. The decline reflects savings from the performance enhancement program, offset in part by the strengthening European and Canadian currencies relative to the U.S. dollar. Operating expenses in 2007 are net of foreign exchange gains of $8.9 million and an actuarial gain of $4.3 million arising from a decision to phase out certain post retirement benefits in the Canadian operations.
Operating expenses as a percentage of revenues were 86.7%, compared with 89.5% in the prior year.
EBITDA Before Repositioning Expenses and EBITDA Margin Before
Repositioning Expenses
On a consolidated basis for the twelve-month period ended October 31, 2007, EBITDA before repositioning expenses, representing earnings from continuing operations before repositioning expenses, asset impairment charges, depreciation and amortization, foreign exchange losses reclassified from other comprehensive income, interest, refinancing expenses, write-off of deferred financing costs, and income taxes was $90.3 million, an increase of $19.4 million, or 27%, from the comparable period in 2006. EBITDA margin before repositioning expenses was 13.3% in the twelve-month period ended October 31, 2007, compared with 10.5% in the same period a year ago.
For the twelve-month period ended October 31, 2007, EBITDA before repositioning expenses excluding the Puerto Rico operations was $108.6 million, compared with $69.5 million in the same period last year. This represents an EBITDA margin before repositioning expenses of 18.8% in 2007, compared with 12.7% in the same period last year.
The Canadian commercial operations reported EBITDA before repositioning expenses of $32.1 million for the twelve months ended October 31, 2007, or $6.9 million higher than the same period last year. This improvement was achieved despite lower Rx and OTC volumes and reflects savings from the performance enhancement program, in particular at the Whitby operations. The improvement also includes a significant portion of the actuarial gains booked in the fourth quarter of 2007 arising from a change in the Company's post retirement benefit plans. EBITDA before repositioning expenses was not significantly impacted by foreign exchange, as the negative earnings impact of the 3% increase in the average Canadian dollar exchange rate relative to the U.S. dollar was offset by foreign exchange gains from the Company's cash flow hedging program.
EBITDA before repositioning expenses from the U.S.A. commercial operations (including Puerto Rico) for the twelve months ended October 31, 2007 was a loss of $7.2 million, compared with a profit of $14.0 million in the same period last year. The decline principally reflects a reduction in Rx manufacturing volumes in the Caguas facility in Puerto Rico. In Cincinnati, volume declines were offset by savings from the performance enhancement program and a change in the revenue mix to higher margin Rx business.
In Europe, EBITDA before repositioning expenses from commercial operations for the twelve months ended October 31, 2007 was $36.9 million, being $10.1 million higher than the same period last year. The improvement reflects increased volumes in the operations in Italy and France, offset in part in Swindon by lower pre-launch revenues for the cephalosporin lyophilization services and fourth quarter production delays. The strengthening European currencies against the US dollar compared with the same period last year also had the impact of increasing EBITDA before repositioning expense by approximately $2.9 million.
EBITDA before repositioning expenses from the global PDS operations for the twelve months ended October 31, 2007 was $30.7 million, being $10.7 million higher than the same period in 2006. This reflects improved profitability arising from growing volumes across all operations.
Corporate costs for the twelve-month period ended October 31, 2007 reflected a net recovery of $0.4 million, compared with costs of $12.4 million for the same period last year. This reported gain included foreign exchange gains of $12.3 million arising from the revaluation of US dollar denominated debt held in the Canadian legal entity. In October 2007 the Company hedged its net US dollar balance sheet exposure, which will reduce future volatility.
Asset Impairment Charge
During the third quarter of 2007 it was determined that the carrying value of the intangible assets and depreciable tangible capital assets (collectively the "long-lived depreciable assets") at the Company's operations in Carolina, Puerto Rico were impaired as a result of volume declines arising from the genericization of Omnicef(R), this being the largest single product that is manufactured at the facility. The Company tested the recoverability of the long-lived depreciable assets at the Carolina operations and determined that the expected future cash flows over the economic life of the principal assets was less than the carrying value of the long-lived depreciable assets. As a result, in the third quarter of 2007, the Company recorded an impairment charge of $48.6 million; $26.1 million for intangible assets and $22.5 million for tangible capital assets. The fair value of the intangible assets was determined using a discounted cash flow methodology and the fair value of the tangible capital assets was based on a weighted average continued use and liquidation value.
During the third quarter of 2006 the Company determined that the carrying value of the long-lived depreciable assets at the Company's operations in Caguas and Manati, Puerto Rico and the goodwill associated with all of the Puerto Rico operations were impaired as a result of certain events which occurred during the third quarter of 2006. These events included: continued deterioration in revenues culminating in a significant increase in losses reported in the third quarter; suspension of production of a major product due to concerns over product shelf life; the risk of a decline in revenue of another major product as a result of the approval by the U.S. Food and Drug Administration of a generic version of the product; and the completion of a long range plan that showed a significant reduction in earnings relative to prior forecasts.
The Company tested the recoverability of the long-lived depreciable assets for all of the Puerto Rico operations and determined that at Caguas and Manati the expected future cash flows over the economic life of the principal assets were less than the carrying value of the long-lived depreciable assets. As a result, in the third quarter of 2006, the Company recorded an impairment charge of $81.4 million; $51.9 million for intangible assets and $29.5 million for tangible capital assets. The fair value of the intangible assets was determined using a discounted cash flow methodology and the fair value of tangible capital assets was based on a value in continued use, taking into account utilization levels.
During the third quarter of 2006 the Company also tested the recoverability of the goodwill associated with Puerto Rico operations using a discounted cash flow methodology, and recorded an impairment charge of $172.5 million representing the full value of the Puerto Rico goodwill.
During the third quarter of 2006 the Company, as part of its ongoing review of long-term investments, concluded that its investment in the shares of a drug technology company which was accounted for on the cost basis had an other than temporary decline and wrote down its value by $0.8 million to its market value as of July 31, 2006.
Repositioning Expenses
During the twelve-month period ended October 31, 2007 the Company incurred $15.8 million of expenses in connection with its performance enhancement program, the site rationalization program in Puerto Rico and Canada and its review of strategic and financial alternatives. The expenses include consulting fees associated with the manufacturing efficiency review, costs associated with reductions in the work force and professional and other costs in connection with the strategic alternatives review.
Depreciation and Amortization Expense
Depreciation and amortization expense was $41.0 million for the twelve months ended October 31, 2007, compared with $38.8 million in the same period of 2006, an increase of $2.2 million, or 6%. The increase principally reflects the effect of the strengthening European and Canadian currencies relative to the U.S. dollar, offset in part by lower depreciation charges from the Puerto Rico operations as a result of the impairment charges booked in the third quarters of 2007 and 2006.
Amortization of Intangible Assets
The amortization of intangible assets was $6.7 million in the twelve months ended October 31, 2007, compared with $11.9 million in the same period of 2006. The amortization of intangible assets relates to the Puerto Rico operations. The charge is lower than for the same period last year due to the impact of the impairment charges made during the third quarters of 2007 and 2006.
Interest Expense and Amortization of Deferred Financing Costs
Interest expense for the twelve months ended October 31, 2007 was $29.2 million, compared with $21.3 million in the same period a year ago. The increase in interest costs in the first half of the year reflected higher debt levels, along with increased borrowing costs as a result of the amendments to the Company's North American loan facilities. The interest expense in the second half of 2007 reflects the impact of the Company's refinancing that was completed on April 27, 2007 and includes a non-cash accretive interest charge of $7.1 million in respect of the debt component of the convertible preferred shares.
In 2007, the Company has adopted CICA Accounting Standard Section 3855 for the accounting of financial instruments, including its policy on deferring costs of obtaining bank and other debt financing (see "Critical Accounting Policies and Estimates"). As a result, amounts that in prior periods were recorded as amortization of deferred financing costs are now recorded in interest expense.
Refinancing Expenses and Write-off of Deferred Financing Costs
All refinancing expenses of $13.5 million for the twelve months ended October 31, 2007 were incurred in connection with the Company's refinancing on April 27, 2007. The expenses are made up of transaction costs for the new credit facilities, transaction costs allocated to the debt portion of the convertible preferred shares and repayment charges in connection with the cancellation of certain of the Company's U.K. debt facilities.
During the first quarter of 2006, the Company incurred charges of $1.6 million in connection with the cancellation and prepayment of certain of its North American credit facilities. The Company also wrote off $6.3 million in related deferred financing costs.
Loss Before Income Taxes from Continuing Operations
The Company reported a loss before income taxes of $65.2 million in the twelve months ended October 31, 2007, compared with a loss of $277.7 million in the same period a year ago.
Income Taxes
The income tax expense for the twelve months ended October 31, 2007 was $19.2 million, compared with an expense of $11.0 million for the same period last year. The income tax charge in 2007 principally reflects high tax rates in Italy where the Company reported significant profits, compounded by tax losses in certain entities in Puerto Rico and Canada, where the tax benefit after valuation reserves has not been recognized. The 2007 expense includes a charge of $2.1 million in connection with an inter-company dividend payment and a charge of $1.9 million in connection with the transfer of net foreign exchange losses from accumulated other comprehensive income. The 2006 charge includes a valuation reserve charge of $6.4 million against future tax asset balances in the Canadian operations.
Loss and Loss Per Share from Continuing Operations
The Company recorded a loss from continuing operations for the twelve months ended October 31, 2007 of $84.5 million, compared with a loss of $288.7 million in the same period a year ago. The loss per share was 91.0 cents compared with $3.11 a year earlier. The loss for the twelve months ended October 31, 2007 included an after-tax asset impairment charge of $47.8 million, or 51.4 cents per share, after tax repositioning expenses of $14.9 million, or 16.0 cents per share and after tax refinancing expenses of $12.6 million, or 13.5 cents per share. The loss for the twelve months ended October 31, 2006 included an after tax asset impairment charge of $252.1 million, or $2.72 per share and after tax costs for debt prepayment charges and the write-off of deferred financing costs of $6.2 million, or 6.6 cents per share.
Because the Company reported a loss in the twelve months ended October 31, 2007 and 2006 there is no impact of dilution.
Earnings (Loss) and Earnings (Loss) Per Share from Discontinued
Operations
The net loss from discontinued operations in the twelve months ended October 31, 2007 was $10.1 million, or 10.9 cents compared with net earnings of $0.6 million or 0.6 cents in the same period last year. The net loss in 2007 includes an asset impairment charge of $12.5 million, or 13.4 cents per share to write down the capital assets to their fair market value less the estimated cost to sell.
Seasonal Variability of Results
Historically, the Company's manufacturing and PDS revenues are lower in the first fiscal quarter. The Company attributes this to several factors, including: (i) many clients reassess their need for additional product in the last quarter of the calendar year in order to use existing inventories of products; (ii) the lower production of seasonal cough and cold remedies; (iii) many small pharmaceutical and small biotechnology clients involved in PDS projects limit their project activity toward the end of the calendar year in order to reassess progress on their projects and manage cash resources; and (iv) the Patheon-wide plant shut-down during a portion of the traditional holiday period in December and January.
Liquidity and Capital Resources
Summary of Cash Flows
The following table summarizes the Company's cash flows for the periods indicated:
Three months ended Twelve months ended
October 31, October 31,
2007 2006 2007 2006
-----------------------------------------------
$ $ $ $
-----------------------------------------------
Net loss from continuing
operations (9,050) (22,162) (84,458) (288,719)
Depreciation and
amortization 11,529 11,858 47,666 50,637
Write-off of deferred
financing costs - - - 6,332
Asset impairment charge - - 48,580 254,661
Foreign exchange loss - - 858 -
Foreign exchange gain on
debt, net of hedging (7,541) - (12,331) -
Amortization of deferred
financing costs 151 346 1,657 944
Employee future benefits,
net of contributions (5,169) 319 (4,846) 1,112
Future income taxes 1,445 (3,514) 4,617 (6,678)
Accretive interest on
convertible preferred
shares 3,573 - 7,054 -
Amortization of deferred
revenues (505) (485) (2,021) (1,978)
Other 1,117 154 2,087 1,587
Working capital 21,742 36,111 (2,442) 20,506
Increase in deferred
revenues 8 - 2,065 9,614
----------- ----------- ----------- -----------
Cash provided by
operating activities 17,300 22,627 8,486 48,018
Cash used in investing
activities (15,542) (25,553) (39,663) (68,845)
Cash provided by (used in)
financing activities (14,932) 32,566 4,221 44,460
Net increase (decrease)
in cash and cash
equivalents from
discontinued operations (1,127) 239 2,830 3,305
Other 4,362 847 3,960 1,278
----------- ----------- ----------- -----------
Net increase (decrease)
in cash and cash
equivalents (9,939) 30,726 (20,166) 28,216
----------- ----------- ----------- -----------
----------- ----------- ----------- -----------
Cash Provided by Operating Activities - Continuing Operations
Cash provided by operating activities from continuing operations was $17.3 million in the fourth quarter of 2007 compared with a $22.6 million for the comparable period in 2006. On a year-to-date basis, cash provided by operating activities from continuing operations was $8.5 million, compared with $48.0 million in the same period last year. The year-to-date deterioration reflects lower earnings before non-cash charges. Cash flows in 2006 also benefitted from a net reduction in the investment in working capital of $20.5 million, compared with an increase in working capital of $2.0 million in 2007. In 2007, the Company received $2.1 million from clients to assist in the funding of capital expenditure projects that are tied to specific manufacturing and supply agreements. This compares with $9.6 million that was received during the same period last year. These amounts are recorded as an increase in deferred revenues and will be recognized as income over the life of the commercial manufacturing contract.
Cash Used in Investing Activities - Continuing Operations
Cash used in investing activities from continuing operations in the fourth quarter of 2007 was $15.5 million, compared with $25.6 million in the same period a year ago. On a year-to-date basis, cash used in investing activities was $39.7 million, compared with $68.8 million in the same period last year. The decrease for the fourth quarter and year-to-date principally reflects lower project related capital expenditures on the cephalosporin lyophilization capacity in the Swindon, U.K. facility. The major expenditures for this expansion were incurred in 2006.
A summary of cash used in investing activities is as follows:
Three months ended Twelve months ended
October 31, October 31,
2007 2006 2007 2006
-----------------------------------------------
$ $ $ $
-----------------------------------------------
Additions to capital
assets
- sustaining (9,166) (7,088) (18,034) (16,975)
- project related (5,519) (17,791) (17,768) (49,617)
Net increase in investments (25) (49) (202) (49)
Increase in deferred
pre-operating costs (832) (625) (3,659) (2,204)
----------- ----------- ----------- -----------
Cash used in investing
activities of continuing
operations (15,542) (25,553) (39,663) (68,845)
----------- ----------- ----------- -----------
----------- ----------- ----------- -----------
Cash Provided by (Used in) Financing Activities
In the fourth quarter of 2007 the Company used $8.8 million of cash to repurchase 2,334,300 of its restricted voting shares under a normal course issuer bid.
The principal financing activity for the twelve months ended October 31, 2007 was the issue, through a private placement, of $150 million of convertible preferred shares of the Company to JLL Partners and the completion of new credit facilities in the aggregate amount of $225 million, comprising of a seven-year $150 million term loan and a five-year $75 million revolving facility. The net proceeds from the JLL Partners investment and the seven-year term loan were used to repay the Company's obligations under its existing North American and U.K. credit facilities.
The principal financing activity during the twelve months ended October 31, 2006 was the completion of new credit facilities in North America in the aggregate amount of $290.0 million to refinance existing debt of the Company and its U.S. subsidiaries. The Company was able to release $7.8 million of restricted cash that had previously been held as security for certain of the cancelled facilities. During the first quarter of 2006 the Company's Italian subsidiary also entered into a new long-term debt facility in the amount of euro 28.5 million ($33.9 million) to replace existing loans.
A summary of cash provided by financing activities is as follows:
Three months ended Twelve months ended
October 31, October 31,
2007 2006 2007 2006
-----------------------------------------------
$ $ $ $
-----------------------------------------------
Increase (decrease) in
bank indebtedness (4,230) 3,041 3,532 (11,096)
Increase in long-term debt 15,456 42,443 198,108 416,389
Repayment of long-term debt (17,380) (11,790) (337,452) (364,800)
Issue of convertible
preferred shares - - 150,000 -
Convertible preferred share
issue costs - equity
component - - (1,213) -
Issue of restricted
voting shares - 47 24 127
Repurchase of restricted
voting shares (8,778) - (8,778) -
Decrease in restricted cash - - - 7,805
Increase in deferred
financing costs - (1,175) - (3,965)
----------- ----------- ----------- -----------
Cash provided by (used in)
financing activities of
continuing operations (14,932) 32,566 4,221 44,460
----------- ----------- ----------- -----------
----------- ----------- ----------- -----------
Financing Arrangements and Ratios
Convertible Preferred Shares
----------------------------
The $150 million 8.5% convertible preferred shares purchased by JLL Partners on April 27, 2007 represent 150,000 units, each consisting of one Class I Preferred Share, Series C (a convertible preferred share) and one Class I Preferred Share, Series D (a special voting preferred share) at a purchase price of $1,000 per unit.
Until October 27, 2009, no cash dividends will be paid, but the liquidation preference and conversion rate will increase on a quarterly basis by 2.125%. After October 27, 2009, these increases in the liquidation preference and conversion rate will continue until the maturity or prior conversion of the convertible preferred shares, unless the Company elects to pay a cash dividend for any applicable quarter, in which case the Company will pay a cash dividend for such quarter based on an annual dividend rate of 8.5% on the aggregate liquidation preference of the convertible preferred shares.
Each convertible preferred share is convertible into 218.7154 Patheon restricted voting shares, as adjusted for any non-cash dividends noted above, at any time at the holder's option. The Company will be entitled to require the holder to convert into restricted voting shares if, at any time after October 27, 2009, the market price of the restricted voting shares on the Toronto Stock Exchange exceeds a price equivalent to US$7.87 for a period of at least 60 days.
If not previously converted, the Company is required to redeem the convertible preferred shares for cash on April 27, 2017 at a price equal to the aggregate liquidation preference of the convertible preferred shares, plus accrued and unpaid dividends thereon. The Company is also required to redeem the convertible preferred shares upon the occurrence of a change of control of Patheon at a price equal to the greater of the aggregate liquidation preference of the convertible preferred shares, plus accrued and unpaid dividends thereon, or the price per share paid to holders of restricted voting shares in the change of control transaction, multiplied by the number of restricted voting shares into which the convertible preferred shares are then convertible.
The convertible preferred shares have the right to vote, together with the holders of the restricted voting shares, on an as-if converted basis, in respect of all matters other than the election of directors. As at October 31, 2007 these voting rights represent approximately 27% of the voting rights of Patheon. The special voting preferred shares have the right to appoint up to three directors.
The convertible preferred shares are considered to be a compound financial instrument with both a debt and equity component. On issuance, the fair value of the debt component was $132.9 million. The remainder of the proceeds, attributable to shareholders' equity was $15.9 million, net of apportioned transaction costs of $1.2 million. See Convertible Preferred Shares in "Critical Accounting Policies and Estimates" below with regard to how the Convertible Preferred Shares have been accounted for.
$225 Million Credit Facilities
------------------------------
On April 27, 2007 the Company completed new credit facilities in the aggregate amount of $225 million, comprising a seven-year $150 million senior secured term loan and a five-year $75 million asset based revolving credit facility. The Company is required to make quarterly installment payments of $375,000 on the term loan facility, along with additional mandatory repayments based on certain excess cash flow measures. Interest on the facilities is at floating rates based on LIBOR, US or CAD prime, or the federal funds effective rate, plus applicable margins. The Company has entered into interest rate swaps to convert the interest expense on the $150 million senior secured term loan from a floating interest rate to a fixed interest rate. The facilities are secured by substantially all of the assets of the Company's operations in Canada, U.S.A., Puerto Rico and the U.K and the Company's investments in the shares of all other operating subsidiaries.
Financial Ratios
----------------
Total interest bearing debt, including the debt component of the convertible preferred shares, at October 31, 2007 was $363.7 million, being $14.1 million higher than at October 31, 2006. At October 31, 2007, the Company's consolidated ratio of interest-bearing debt to shareholders' equity was 184.4%, compared with 139.4% at October 31, 2006. The increase principally reflects the reduction in shareholders' equity arising from the losses that the Company has incurred in the twelve months ended October 31, 2007.
Adequacy of Financial Resources
With the completion of the new financing arrangements on April 27, 2007, the Company believes that its financial resources are sufficient to fund projected capital expenditures, debt service requirements and employee future benefit obligations in the normal course of business. The risks associated with going concern uncertainty reported in the Company's 2006 Annual Report have now been eliminated.
Critical Accounting Policies and Estimates
Changes in and Significant New Accounting Policies
Effective November 1, 2006 the Company adopted the Canadian Institute of Chartered Accountants Handbook Section 3855 "Financial Instruments - Recognition and Measurement", Section 3865 "Hedges", Section 1530 "Comprehensive Income" and Section 3861 "Financial Instruments - Disclosure and Presentation". The adoption of the new standards resulted in changes in accounting for financial instruments and hedges as well as the recognition of certain transition adjustments that have been recorded in accumulated other comprehensive income. The comparative interim consolidated financial statements have not been restated, except for the reclassification of amounts previously recorded as cumulative translation adjustment, which are now included in accumulated other comprehensive income. For a description of the principal changes in accounting policy see Note 1 to the consolidated financial statements.
In the second quarter of 2007 the Company changed its accounting policy relating to costs of obtaining bank and other debt financing. Under the new policy all transaction costs, including fees paid to advisors and other related costs, are expensed as incurred. Financing costs, including underwriting and arrangement fees paid to lenders are deferred and netted against the carrying value of the related debt and amortized into interest expense using the effective interest rate method. The Company previously deferred all transaction and financing costs associated with obtaining bank and other debt financing. Under the new requirements of CICA Handbook Section 3855, all deferred costs are netted off against the fair value of the debt. The Company believes that the new policy is reliable and more relevant as it results in a more transparent treatment of transaction costs that the Company has incurred in its recent refinancing activities and in the carrying value of debt. The change in policy has been made retrospectively effective November 1, 2006 and had the effect of increasing the retained deficit at November 1, 2006 by $1.7 million and reducing the interest expense and net loss for the three months ended January 31, 2007 by $0.6 million.
As a result of the issuance of the convertible preferred shares on April 27, 2007, the Company has also added a new accounting policy for convertible preferred shares as detailed below.
General
Patheon's significant accounting policies are described in Note 1 to the 2006 audited consolidated financial statements. The most critical of these policies are those related to revenue recognition, deferred revenues, intangible assets, impairment of long lived depreciable assets, goodwill, employee future benefits, and income taxes, (Notes 1, 7, 9, 13 and 17 of the 2006 audited consolidated financial statements).
The preparation of the consolidated financial statements in conformity with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect: the reported amounts of assets and liabilities; the disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and the reported amounts of revenue and expenses in the reporting period. Management believes that the estimates and assumptions used in preparing its consolidated financial statements are reasonable and prudent; however, actual results could differ from those estimates.
The Company's accounting policies have been reviewed and discussed with the Company's Audit Committee.
Revenue Recognition
The Company recognizes revenue for its commercial manufacturing and pharmaceutical development services when services are completed in accordance with specific agreements with its clients and when all costs connected with providing these services have been incurred, the price is fixed or determinable and collectibility is reasonably assured. Client deposits on pharmaceutical development services in progress are included in accounts payable and accrued liabilities.
The Company does not receive any fees on signing of contracts. In the case of pharmaceutical development services, revenue is recognized on the achievement of specific milestones in accordance with the respective development service contracts. In the case of commercial manufacturing services, revenue is recognized when services are complete and the product has met rigorous quality assurance testing.
Deferred Revenues
The costs of certain capital assets are reimbursed to the Company by the pharmaceutical companies that are to benefit from the improvements in connection with the manufacturing and packaging agreements in force. These reimbursements are recorded as deferred revenues and are recognized as income over the remaining minimum term of the agreements. During the fourth quarter of 2007, $0.5 million was recognized as earnings. During the twelve months ended October 31, 2007, $2.0 million was recognized as earnings and $2.1 million was received as a capital expenditure reimbursement.
Intangible Assets
Intangible assets represent the values assigned to acquired client contracts and relationships. They are amortized on a straight-line basis over their estimated economic life. During the fourth quarter of 2007, $1.1 million was charged to earnings. During the twelve months ended October 31, 2007, $6.7 million was charged to earnings.
Impairment of Long-Lived Depreciable Assets
On an ongoing basis, the Company reviews whether there are any indicators of impairment of its capital assets and identifiable intangible assets ("long- lived depreciable assets"). If such indicators are present, the Company assesses the recoverability of the assets or group of assets by determining whether the carrying value of such assets can be recovered through undiscounted future cash flows. If the sum of undiscounted future cash flows is less than the carrying amount, the excess of the carrying amount over the estimated fair value, based on discounted future cash flows, is recorded as a charge to net earnings. In the third quarter of 2007 the Company recorded an impairment charge of $48.6 million relating to the long-lived depreciable assets in Carolina, Puerto Rico.
Valuation of Goodwill
The Company evaluates goodwill for impairment at least annually and reviews if there are any indicators of impairment on an ongoing basis. If the carrying value of the reporting unit exceeds its fair value, the fair value of the reporting units goodwill, determined in the same manner as in a business combination, is compared with its carrying amount to measure the amount of any impairment loss, if any.
The goodwill shown on the financial statements for the period ended October 31, 2007 was $3.7 million and relates to the acquisition in 2000 of the remaining shares of Global Pharm Inc., which now operates as Toronto York Mills Operations. The goodwill and the business supporting its value will be transferred to the Whitby operations on the closure of the York Mills facility.
Income Taxes
In accordance with Canadian GAAP, the Company uses the liability method of accounting for future income taxes and provides for future income taxes for significant temporary timing differences.
Preparation of the consolidated financial statements requires an estimate of income taxes in each of the jurisdictions in which the Company operates. The process involves an estimate of the Company's current tax exposure and an assessment of temporary differences resulting from differing treatment of items such as depreciation and amortization for tax and accounting purposes. These differences result in future tax assets and liabilities and are reflected in the consolidated balance sheet.
Future tax assets of $31.1 million have been recorded at October 31, 2007. The future tax assets are primarily composed of accounting provisions related to pension and post-retirement benefits not currently deductible for tax purposes, the tax benefit of net operating loss carry forwards related to the U.K., unclaimed R&D expenditures and deferred financing and share issue costs. The Company evaluates quarterly the ability to realize its future tax assets. The factors used to assess the likelihood of realization are the Company's forecast of future taxable income and available tax planning strategies that could be implemented to realize the future tax assets.
Future tax liabilities of $47.6 million have been recorded at October 31, 2007. This liability has arisen primarily on tax depreciation in excess of book depreciation.
The Company's tax filings are subject to audit by taxation authorities. Although management believes that it has adequately provided for income taxes based on the information available, the outcome of audits cannot be known with certainty and the potential impact on the financial statements is not determinable.
Convertible Preferred Shares
On April 27, 2007 the Company issued $150.0 million of convertible preferred shares. The shares are considered to be a compound financial instrument that contains both a debt component and an equity component.
On issuance of the convertible preferred shares, the fair value of the debt component is determined by discounting the expected future cash flows using a market interest rate for a non-convertible debt instrument with similar terms. The resulting value is carried as debt on an amortized cost basis until extinguished on conversion or redemption. The remainder of the proceeds is allocated as a separate component of shareholders' equity, net of transaction costs. Transaction costs are apportioned between the debt and equity components based on their respective carrying amounts when the instrument was issued.
On conversion, the carrying amount of the debt component and the equity component are transferred to share capital and no gain or loss is recognized.
Employee Future Benefits
The Company provides to certain retired employees pensions and post- employment benefits, including medical benefits and dental care. The determination of the obligation and expense for defined benefit pensions and post-employment benefits is dependent on the selection of certain assumptions used by actuaries in calculating such amounts. Those assumptions are disclosed in note 13 to the Company's 2006 audited consolidated financial statements.
Risk Management
The following are updates to certain risks and uncertainties described in the Company's Management's Discussion and Analysis for the year ended October 31, 2006, available on SEDAR (www.sedar.com) or on Patheon's website (www.patheon.com).
Foreign Currency
The Company's business activities are conducted in several currencies - Canadian dollars and U.S. dollars for the Canadian operations, U.S. dollars for the U.S. operations and euros and U.K. sterling for the European operations.
Since the European and U.S. operations conduct business principally in their respective local currencies, the exposure to foreign currency gains and losses is not significant. However, the Company's Canadian operations negotiate sales contracts for payment in both U.S. and Canadian dollars, and materials and equipment are purchased in both U.S. and Canadian dollars. The majority of its non-material costs (including payroll, facilities' costs and costs of locally sourced supplies and inventory) are denominated in Canadian dollars. Approximately 70% of revenues of the Canadian operations and approximately 20% of its operating expenses are transacted in U.S. dollars. As a result, the Company may experience trading and translation gains or losses because of volatility in the exchange rate between the Canadian dollar and the U.S. dollar. Based on the Company's current U.S. denominated net inflows, for each one-cent change in the Canadian-U.S. rate, the impact on annual pretax earnings, excluding any hedging activities, is approximately $0.9 million.
The Company mitigates its foreign exchange risk by engaging in foreign currency hedging activities using derivative financial instruments. At October 31, 2007 the Company had outstanding foreign exchange forward contracts to sell US$34.2 million at an exchange rate of $1.0535 Canadian. The contracts mature at the latest on April 21, 2008 and cover approximately 75% of the Company's expected foreign exchange exposure for the first half of the 2008 fiscal year. The mark-to-market value at October 31, 2007 that is recorded in accumulated other comprehensive income is an unrealized gain of $4.1 million. At October 31, 2007 the Company also had an outstanding foreign exchange forward contract to buy US$45.0 million at an exchange rate of $1.0015 Canadian. The contract matures on January 28, 2010 and hedges the Canadian operations US dollar balance sheet exposure. The mark-to-market value at October 31, 2007 that is recorded in earnings is an unrealized loss of $2.7 million. The Company does not purchase any derivative instruments for speculative purposes.
Translation gains and losses related to the carrying value of the Company's foreign operations and certain foreign currency denominated debt held by the Company and designated as a hedge against the carrying value of certain foreign subsidiaries, are included in accumulated other comprehensive income in shareholders' equity. At October 31, 2007, the Company had designated $141.6 million of US dollar denominated debt as a hedge against its investment in its U.S.A. and Puerto Rico subsidiaries.
Interest Rate Exposure
The Company has exposure to movements in interest rates. The Company has entered into interest rate swaps to convert the interest expense on the $150 million senior secured term loan from a floating interest rate to a fixed interest rate. Taking this interest rate swap into account, at October 31, 2007, 19% of the Company's total debt portfolio, including the debt component of the convertible preferred shares, was subject to movements in floating interest rates. Assuming no change to the structure of the debt portfolio, a 1% change in floating interest rates has an impact on annual pre-tax earnings of approximately $0.7 million.
Effectiveness of Disclosure Controls and Internal Controls
Disclosure controls and procedures are designed to provide reasonable assurance that all relevant information is gathered and reported to senior management, including the Chief Executive Officer ("CEO") and the Chief Financial Officer ("CFO"), on a timely basis so that appropriate decisions can be made regarding public disclosure. An evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures was conducted as of October 31, 2006 by and under the supervision of the Company's management, including the CEO and the CFO. Based on this evaluation, the CEO and the CFO have concluded that the Company's disclosure controls and procedures (as defined in Multilateral Instrument 52-109 - Certification of Disclosure in Issuers' Annual and Interim Filings of the Canadian Securities Administrators) are effective to ensure that the information required to be disclosed in reports that the Company files or submits under Canadian securities legislation is recorded, processed, summarized and reported within the time periods specified in such legislation. There have been no changes, since this last formal assessment, that have materially affected, or are reasonably likely to materially affect the Company's disclosure controls and procedures.
Under the supervision of the CEO and CFO, the Company has designed internal controls over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. This design evaluation included documentation activities, management inquiries and other reviews as deemed appropriate by management in consideration of the size and nature of the Company's business. There were no changes in the Company's internal controls over financial reporting during the most recent interim period that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.
Selected Quarterly Financial Information
The following is selected financial information for the eight most recent quarters:
EARNINGS (LOSS)
NET PER SHARE FROM
QUARTER ENDED EBITDA EARNINGS CONTINUING
(In thousands of BEFORE (LOSS) FROM OPERATIONS
U.S. dollars, REPOSITIONING CONTINUING ------------------
except per REVENUES EXPENSES OPERATIONS Basic Diluted
share amounts) $ $ $ $ $
-------------------------------------------------------------------------
2007
October 31 166,792 21,234 (9,050) ($0.10) ($0.10)
July 31 175,508 23,138 (50,668) ($0.55) ($0.55)
April 30 171,966 23,153 (22,552) ($0.24) ($0.24)
January 31 162,808 22,793 (2,188) ($0.02) ($0.02)
2006
October 31 165,750 18,762 (22,162) ($0.24) ($0.24)
July 31 178,739 14,990 (257,698) ($2.78) ($2.78)
April 30 180,157 23,244 2,549 $0.03 $0.03
January 31 150,013 13,880 (11,408) ($0.12) ($0.12)
Additional Information
Share Capital
As of October 31, 2007, the Company had 90,624,388 restricted voting shares (previously common shares) outstanding and 150,000 each of Class I Preferred Shares, Series C (convertible preferred shares) and Series D (special voting preferred shares).
On October 9, 2007 the Company announced that it would undertake a normal course issuer bid to repurchase up to 4.6 million of its restricted voting shares. By October 31, 2007 the Company had repurchased 2.3 million restricted voting shares under this program for a net cost of $8.8 million.
The Company's articles were amended on April 26, 2007 to redesignate the common shares as restricted voting shares. This occurred in connection with the issuance of the convertible preferred shares. The holders of the special voting preferred shares have the right to elect up to three of nine members of the Board of Directors. The holders of Patheon's restricted voting shares have the right to elect the remaining members of the Board of Directors. Under the rules of the Toronto Stock Exchange, voting equity securities are not to be designated, or called, common shares unless they have a right to vote in all circumstances that is not less, on a per share basis, than the voting rights of each other class of voting securities. Accordingly, the Company has amended its articles to redesignate the common shares as restricted voting shares. This redesignation involves only a change in the name of the securities; the number of shares outstanding and the terms and conditions of the outstanding shares are not affected by the change.
Public Securities Filings
Other information about the Company, including the annual information form and other disclosure documents, reports, statements or other information that is filed with Canadian securities regulatory authorities can be accessed through SEDAR at www.sedar.com.
Outlook
Due to normal shut downs during December, revenues in the first quarter of 2008 are expected to be lower than the fourth quarter of 2007.
Auditor Review
The accompanying unaudited interim consolidated financial statements of the Company have been prepared by and are the responsibility of management. The Company's independent auditor has not performed a review of the financial statements for the three-month and twelve-month periods ended October 31, 2007, or for the comparative periods ended October 31, 2006.
FORWARD-LOOKING STATEMENTS
This news release and MD&A contains forward-looking statements which reflect management's expectations regarding the Company's future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as "plans", "expects" or "does not expect", "forecasts", "anticipates" or "does not anticipate", "believes", "intends" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved have been used to identify these forward-looking statements. Although the forward-looking statements contained in this news release and MD&A reflect management's current assumptions based upon information currently available to management and based upon what management believes to be reasonable assumptions, the Company cannot be certain that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause the Company's actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: the market demand for client products; credit and client concentration; the ability to identify and secure new contracts; regulatory matters, including compliance with pharmaceutical regulations; management of expanded operations; international operations risks; currency; competition; product liability claims; intellectual property; environmental; and interest rates. Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this news release and MD&A and, except as required by law, the Company assumes no obligation to update or revise them to reflect new events or circumstances.